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Abstract: Traumatic brain injury (TBI), defined as an alteration in brain functions caused 
by an external force, is responsible for high morbidity and mortality around the world.  
It is important to identify and treat TBI victims as early as possible. Tracking and  
monitoring TBI with neuroimaging technologies, including functional magnetic resonance 
imaging (fMRI), diffusion tensor imaging (DTI), positron emission tomography (PET),  
and high definition fiber tracking (HDFT) show increasing sensitivity and specificity.  
Classical electrophysiological monitoring, together with newly established brain-on-chip, 
cerebral microdialysis techniques, both benefit TBI. First generation molecular biomarkers, 
based on genomic and proteomic changes following TBI, have proven effective and 
economical. It is conceivable that TBI-specific biomarkers will be developed with the 
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combination of systems biology and bioinformation strategies. Advances in treatment of 
TBI include stem cell-based and nanotechnology-based therapy, physical and pharmaceutical 
interventions and also new use in TBI for approved drugs which all present favorable 
promise in preventing and reversing TBI. 
Keywords: traumatic brain injury; neuroimaging; electrophysiology; stem cell; hypothermia; 
nano particle; biomarker; microdialysis; proteomic; genomic 
 
 
1. Introduction 
Traumatic brain injury (TBI) is characterized as “an alteration in brain function, or other evidence 
of brain pathology, caused by an external force” [1] and is present in all societies as the most severe, 
disabling neurological disorder for more than 57 million patients worldwide [2]. TBI occurrence peaks 
during both youth and later in life, and is one of the most common causes of morbidity and mortality 
of young adults less than 45 years of age [3]. The World Health Organization anticipates that it will be 
ranked as a dominant cause of death and disability by the year 2020 [4]. Furthermore, it is estimated 
that approximately 1.7 million people experience TBI each year in the United States [5]. In Europe, 
estimated annual health care cost exceeds 33 billion euros for this type of injury [6]. Among those 
injured, many individuals will have physical disability leading not only to a burden on the health care 
system but more importantly, functional impairments impeding quality of life [7–9]. TBI can also lead 
to outcomes of physical inactivity such as obesity, diabetes, and heart disease [10–13]. It is quite 
imperative to trace, monitor and treat TBI more efficiently with the aid of advanced technologies and 
multiple therapeutic strategies. In this review, we shall systematically summarize the related progress 
in these aspects with emphasis on updated information. 
It wasn’t until 1976 that Graham Teasdale and Bryan J. Jennett came up with a method to 
objectively diagnose unconsciousness, as TBI may be associated with loss of consciousness. They 
established the Glasgow Coma Scale (GCS) [14]. With the GCS, rapid assessment of possible brain 
pathologies can be done by measuring spontaneous and stimulated verbal, motor or eye opening 
responses, thus allowing evaluation of best response. The length of unconsciousness dictates the 
severity of brain injury.  
Mild, moderate and severe TBIs are classified according to GCS scores of 13–15, 9–12, and 3–8, 
respectively. Severe injury causes not only permanent neurological deficits (20% of adults) but it has 
been shown that up to 14% remain in a vegetative state and 20%–40% of patients end up dying as a 
result of brain injury or secondary complications [2]. Over the past two decades, several studies 
demonstrated that a significant amount of central nervous system damage occurring after TBI resulted 
from secondary brain injuries [1–4], which involves a complex cascade of biochemical events 
eventually leading to delayed tissue damage and cell death [5,6]. 
Conventional neuroimaging methods, like CT and MRI, show advantages in detecting secondary 
injuries. However, newly developed structural and functional neuroimaging techniques such as  
diffusion-tensor-imaging, magnetoencephalography and single-photon-emission-computed-tomography 
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improve accuracy and timeliness of diagnosis and prognosis in TBI. We will introduce and compare the 
most current methods used in clinical settings. Compared to advanced neuroimaging technologies, 
detecting molecular biomarkers in biofluid like blood, cerebrospinal fluid, urine, saliva, etc. is more 
feasible and effective in diagnosis, prognosis and treatment guidance of TBI. At the genomic and 
proteomic levels, modern bioinformation helps to explore more specific and sensitive TBI-restricted 
biomarkers for early diagnosis and long-term prognostication. Multimodal neuromonitoring technology 
has been shown to play an important role in treatment of TBI, preventing secondary brain injury and 
promoting better patient outcome. Here we shall introduce the traditional monitoring methods including 
electrophysiologic monitoring, brain oxygen monitoring, intracranial pressure (ICP) monitoring, cerebral 
microdialysis and experimental brain-on-chip technology. 
For the treatment of TBI, we shall focus on updated information about stem-cell based and 
nanotechnology-based therapies like perfluoro-carbons and polyethylene-glycol-functionalized 
hydrophilic-carbon-clusters and also cover the physical and pharmaceutical interventions like 
hypothermia and hyperbaric oxygen preconditioning. New uses in TBI treatment for approved drugs 
like progesterone and lithium are also discussed. 
2. Gene Expression Profiles after TBI 
Advances in technology include but are not limited to: single-nucleotide polymorphisms, global 
gene expression approach, microarray techniques, mass spectrometry, wide genomic, transcriptomic, 
proteomic and epigenomic profiling approaches, gene interaction hierarchy, and Ingenuity Pathway 
Analysis program. Through these technologies, a substantial amount of genetic factors have proven to 
be implicated in the pathogenesis of brain trauma. Evaluating the influence of polymorphisms on TBI 
helps to better understand the individual variations in outcomes, aids in the triaging and management 
of TBI patients, and ultimately contributes to genetic profile-based personalized interventions [7]. 
2.1. Genetic Polymorphisms Influence Recovery 
Clinical outcomes following TBI are determined by both multiple genetic elements and  
acquired environmental risk factors. TBI triggers a series of pathophysiological processes including 
neuroinflammation, oxidative stress, excitotoxicity, apoptotic cell death, neurodegeneration, reparative 
processes, synaptic plasticity, and neurotransmitter alterations [7,8]. Additionally, genetic factors have 
been implicated in almost all these processes to some extent and are therefore responsible for the 
variable individual responses to TBI [7–9]. An individual’s genetic predisposition to the injury may 
influence the variability of the initial response, the recovery process, susceptibility to secondary injury, 
and response to rehabilitation. 
Genetic association studies are useful tools in investigating possible relationships between gene 
polymorphisms and disease outcome. With the microarray techniques, Michael and colleagues [10] 
detected 5000 gene expressions in brain tissue from four TBI subjects, one subject with vacuities, and 
one subject with normal brain tissue. They found that 1200 gene segments increased their expressions 
and 104 transcripts showed differential expressions. The candidate genes affecting TBI outcomes 
include apolipoprotein E (APOE), p53, angiotensin I-converting enzyme (ACE), D2 subtype of the 
dopamine receptor (DRD2), atechol-O-methyltransferase (COMT), BCL-2, neuroglobin (NGB) and 
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IL-1β [11]. Genetic susceptibility to clinical outcomes after TBI was reported in recent clinical studies, 
as the genetic loci showed close link with the clinical phenotype including polymorphisms in APOE, 
brain-derived neurotrophic factor (BDNF), endothelialnitric oxide (NOS3), monoamine oxidase A 
(MAO-A), interleukin 6 (IL-6), neurofilament heavy (NEFH), serotonin transporter protein (SLC6A4), 
COMT, calcineurincatalytic isoform A-gamma subunit (PPP3CC), and kidney and brain expressed 
protein (KIBRA) genes [8]. 
Previous studies investigated genetic variants involved in various molecular pathways initiated  
after TBI, including oxidative stress, neuroinflammation, excitotoxicity, apoptotic cell death, 
neurodegeneration, reparative processes, synaptic plasticity, and neurotransmitter alterations [7–9]. 
Given the multiple biological processes involved in the pathogenesis of neurotrauma, the majority of 
genetic factors that influence TBI outcomes remain unknown. There may be several other relevant 
genes awaiting identification, and detection of these genes requires a combination of wide genomic, 
transcriptomic, proteomic and epigenomic-profiling approaches [8,12]. 
Gene expression and epigenetic-epigenomic approaches studies have been conducted on nonhuman 
TBI models to understand the pathophysiology and recovery process after TBI. With a global gene 
expression approach, Di Pietro and colleagues found that gene expression regulation in rat 
hippocampus was determined by the severity of injury, and the associated pathways that were altered 
the most were those involved in inflammation, immunity, and neurodegeneration [13]. A candidate 
gene study in mouse hippocampal tissue also showed activation of inflammation pathways after TBI, 
with up-regulation of inflammatory genes starting at the site of injury, spreading throughout the 
hippocampus, and thus preceding the onset of secondary injury [12,14]. 
2.2. Local and Remote Gene Expression Profiles 
Bioinformatic analysis tools allow for both identification of key molecules and elucidation of their 
interactions. It made the utilization of microarray data more practical and easily replicable. Based on a 
database built from published scientific literature, Ingenuity Pathway Analysis (IPA) software is 
designed to depict direct and indirect gene interactions and to assign genes to specific biological 
functions and canonical pathways [8]. When compared to the non-injured control brain, the 
information of local and remote gene expression profiles will provide us with valuable insight into 
delayed neuronal injury as well as endogenous neuroprotective mechanisms. White and colleagues 
utilized the IPA program to analyze the pathways and networks related to TBI-induced genetic 
alterations. They first examined gene expression on both sides of the brain; data showed that a robust 
proinflammatory response was associated with TBI in ipsilateral brain tissues. Interestingly, the 
contralateral side of the brain also exhibited significant gene expression changes after TBI, which 
suggested a remote anti-inflammatory response. Furthermore, they used multiple network and pathway 
approaches to identify genes of interest (GOI) and revealed two distinct pathways associated with  
post-TBI secondary neural injury. They include toll-like receptor/NF-κB signaling pathway and 
JAK/STAT signaling pathway. These genes of interest identified molecules and molecular pathways in 
response to TBI and could provide novel targets for therapeutic strategies [15]. 
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2.3. miRNAs Expression Profiles 
miRNAs are small RNA (~22 nts) molecules that are expressed intrinsically and play an key role in 
regulating gene expression. miRNAs have proven to be important mediators of the massive molecular 
and cellular changes that occur in both short and long-term periods post TBI. In a study of rodent TBI 
models, deep sequencing identified eight upregulated and thirteen downregulated miRNAs at 24 h 
post-injury, whereas three were upregulated and thirteen downregulated at day 7 post-injury [16]. 
Microarray analyses in rat models of TBI revealed dynamic temporal regulation of miRNA expression 
within the cortex, with the numbers of downregulated and upregulated miRNAs peaking at 24 h and  
72 h post-injury respectively [17,18]. In the mouse hippocampus, 50 miRNAs were decreased, whereas 
thirty-five miRNAs were increased after TBI [19]. Bioinformatic analysis of the predicted targets for 
validated miRNAs regulated by TBI (miR-107, -130a, -223, -292-5p, -433-3p, -451, -541, and -711) 
revealed an overrepresentation of proteins involved in several biological processes and functions 
initiated after injury, including signal transduction, transcriptional regulation, proliferation, and 
differentiation. Redell and colleagues further observed how miR-21 was upregulated in hippocampus, 
particularly in the dentate gyrus and CA3 region in a TBI model [20]. Expression of cell death protein 
4 as a target of miR-21 decreased in these regions, denoting a potential survival mechanism mediated 
by miR-21in TBI-affected cells [21]. 
Mechanical force is one of important determinants in TBI, and Weber and colleagues proposed how 
mechanical shear stresses could modulate vascular homeostasis through microRNA regulation of target 
molecules, like phosphatase and tensin homologprotein (PTEN) [22]. They conducted a study on 
human endothelial cells subjected to unidirectional shear stress, and data showed 13 microRNAs  
with increased expressions; among them miR-21 was expressed the most. miR-21 targets phosphatase  
and PTEN. Further studies in human vascular endothelial cells exposed to shear stress or transfected  
with miR-21 showed downregulation of PTEN, whereas cells overexpressing miR-21 had decreased  
apoptosis, increased phosphorylation of endothelial nitric oxide synthase, and nitric oxide production [22]. 
Together, they concluded shear stress could regulate microRNA expression in endothelial cells, 
thereby suggesting potential roles of microRNAs on mechanotransduction and injury response [23]. In 
addition Redell and colleagues [24], firstly reported plasma miRNA levels altered in TBI patients 
compared to age-, gender-, and race-matched healthy volunteers. Based on quantitative analysis of  
RT-PCR data, they suggested that plasma miR-16, miR-92a, and miR-765 be used as early circulating 
markers which will be discussed more detail in the subsequent section. 
3. Biochemical Markers for TBI Diagnosis, Prognosis and Management 
TBI accounts for one third of all injury-related deaths [25]. Seventy-five percent of TBIs are 
concussions or other forms of mild TBI. For severe and moderate TBI, neuroimaging and 
electrophysiological modalities as biomarkers are being routinely used in the clinical setting to help 
TBI diagnosis and prognosis, but for mild and chronic TBI, the molecular biomarkers detected in 
biofluids like blood serum, urine, saliva, cerebrospinal fluid (CSF), and extracellular fluid (ECF) are 
more practical and economical. Sensitive and specific biomarkers reflecting brain injuries, repair, and 
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regeneration can provide important information regarding TBI pathophysiology and can serve as 
candidate markers for predicting abnormal computed tomography findings in mild TBI [26]. 
3.1. miRNAs as Diagnostic and Prognostic Biomarkers 
As discussed above, miRNAs expression pattern altered significantly in response to TBI, and 
miRNAs play key roles in signal transduction, transcriptional regulation, mechanotransduction, 
proliferation, and differentiation initiated by TBI. These altered miRNAs thus seem to be good 
candidate biomarkers for TBI. Redell and colleagues compared the plasma miRNA profiles between 
severe TBI patients (Glasgow Coma Scale ≤ 8) and healthy volunteers. They concluded that decreases 
in the levels of miR-16 and miR-92a, and increased levels of miR-765, were good markers of severe 
TBI at 25–48 h after injury [27]. A simplified technique for miRNA measurement in biofluids could 
provide rapid diagnosis and allow for efficient treatment decisions [28]. 
Studies of CSF from TBI rats found a significant increase in levels of miR-let-7i as early as 3 h 
post-injury [29]. Prediction analysis revealed that miR-let-7i targets S100B and UCH-L1 which are 
TBI-related proteins, suggesting a possible role for miR-let-7i in regulating TBI pathology [30]. Three 
other miRNAs—miR-16, miR-92a, and miR-765 have been identified to serve as diagnostic 
biomarkers for severe brain injury in TBI patients. Plasma levels of miR-16 and miR-92a are also 
increased notably in patients with mild TBI [24]. These studies highlighted how the miRNA-based 
biomarkers in the serum and CSF could serve as promising diagnostic tools in TBI [18]. 
In addition, miRNA levels also change following TBI treatment, suggesting the use of miRNA as a 
prognostic biomarker. As will be discussed in the treatment section, hypothermia is one of the most 
promising treatments for TBI due to its ability to attenuate prolonged neurological deficits and 
improve functional outcomes [31–33]. Interestingly, some miRNAs that show altered expression after 
TBI are also sensitive to temperature change. In a rat fluid-percussion model of TBI, the levels of 
many upregulated miRNAs after TBI decreased under hypothermic conditions [34]. Among the 
miRNAs, miR-9 is predicted to reduce expression of proteins known to interact with actin-binding 
proteins and basal plasma membranes, indicating that an increase in miR-9 levels after TBI would 
disrupt cytoskeleton and cell-adhesion properties, thereby increasing cell death. Therefore, decreased 
expression of miR-9 may enhanced cell survival and help in explaining the treatment efficacy of 
hypothermia therapy [18]. 
3.2. Serum Autoantibodies as Long-Term Biomarkers 
The permeability of the blood-brain-barrier (BBB) is increased following TBI and results in the 
exposure of brain-specific proteins (potential antigens) and their break down products (BDPs) to 
peripheral circulation immune system components, allowing the self antigen/immune cell interaction 
to activate the immune response post TBI. In the case of TBI, neuronal and glial cells at and around 
damage sites release brain-derived cell-type-specific proteins into the peripheral blood stream, leading 
to a subsequent increase in the formation of autoantibodies against these cells [35]. Several antigens 
and their corresponding autoantibodies have been identified and characterized. Here we highlight the 
potential use of autoantibodies as candidate blood biomarkers due to their long-term presence in serum 
compared to their counterpart antigens. 
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The presence of these autoantibodies may represent putative long-term biomarkers possibly 
correlated to injury severity as well disease prognostic indicators that may be the center for potential 
neurotherapeutic targets (see Table 1). It is conceivable that assessing the levels of these 
autoantibodies in combination with other markers may yield valuable clinical information; however, 
further studies are necessary to correlate the pattern of expression against clinical outcomes at different 
time points post-TBI. 
Table 1. Auto-antibodies as diagnostic marker and/or prognostic factor in traumatic brain 
injuries (TBI). 
Serum Auto-Antibodies Significance Reference 
Anti-GFAP and GFAP break 
down products (BDPs) 
Strong diagnostic marker 
and prognostic factor 
Zhang et al. 2014 [36] 
Anti-BMP (basic myelinprotein) 
Weak diagnostic marker 
and prognostic factor 
Ngankam et al. 2011 [37] 
Anti-PL (phospholipid) 
Weak diagnostic marker 
and prognostic factor 
Ngankam et al. 2011 [37] 
Anti-NMDA and Anti-AMPA Moderate prognostic factor Goryunova et al. 2007 [38] 
3.3. Early Generation Biomarkers 
Clinical proteomics aim to identify suitable biomarkers for diagnosis or prognosis of a disease. The 
current available protein and gene biomarkers are regarded as early generation biomarkers and in some 
regards show low specificities and sensitivities. These early generation biomarkers, however, are well 
studied and some of them have already been applied in clinical practice. We will give a brief overview 
on them. Representative biomarkers are derived from acute neuronal, axonal, astroglial and endothelial 
injuries or secondary inflammatory and reparative processes such as inflammation, oxidative stress, 
excitotoxicity, and other host-derived pathophysiological mechanisms [39]. In particular, early 
biomarkers of structural damage, such as S-100B, GFAP, and UCH-L1 may be used to assist 
physicians in assessing a brain injury and determining whether to order a head CT scan for patient with 
a mild TBI. Markers become abnormal days or weeks after injury and could be used to predict 
prolonged complications or to monitor recovery. Accumulating amounts of molecular biomarkers  
have been found to be associated with TBI outcome and recovery. In Table 2, we list the biomarkers 
derived from damaged structure of neurons, glial cells and endothelial cells. For the numerous other 
biomarkers involving inflammatory reactions, excitotoxicity, oxidative reactions etc. related reviews 
are recommended [40]. 
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Table 2. Potential molecular biomarkers in TBI. 
Candidate Marker Marker Origins Attributes References 
pNF-H (Phosphorylated Neurofilament H) Neuron 
Neuronal injury Blood levels of pNF-H levels showed significant 
correlations with the level of consciousness and CT findings 
Ghonemi et al., 
2013 [41] 
NSE (neuron-specific enolase) Neuron 
Neuronal injury Neuron-specific Elevated blood NSE levels have 
been linked to poor outcome in severe and mild TBI 
Topolovec-Vranic 
et al., 2011 [42] 
SBDP150/SBDP145 (spectrin breakdown products) 
(Calpain-generated) αII-spectrin proteolysis 
Axons and 
presynaptic terminals 
Acute necrosis High level is associated with worse Glasgow Coma 
Scale (GCS), longer ICP elevation, and poor outcome following TBI 
Mondello et al., 
2010 [43] 
SBDP120 (caspase-3-generated) 
Axons and 
presynaptic terminals 
Delayed apoptosis Underlying cell death mechanisms 
Brophy et al., 
2009 [27] 
UCH-L1 (ubiquitin carboxyl-terminalhydrolase-L1) Neuronal cell body 
Neuronal cell body injury sensitive and specific biomarker  
elevated UCH-L1 levels are associated with lower Glasgow  
Coma Scale (GCS) and poor outcome after TBI 
Papa et al.,  
2012 [44] 
MAP2 (microtubule-associated protein 2) Dendrites Dendritic injury 
Kobeissy et al., 
2006 [45] 
MBP (myelin basic protein) 
Oligoden-drocytes/ 
Schwann cells 
Demyelination Excellent specificity, limited sensitivity 
Berger et al.,  
2005 [46] 
S100B (Calcium-Binding Protein B) and its 
isoforms s100A1B and s100BB 
Glia cells 
Glial injury Elevated blood and urine levels of s100b,  
100A1B and s100BB are associated with poor outcome in TBI 
Rodriguez et al., 
2012 [47] 
GFAP (glialfibrillary acidic protein) Glia cells 
Glial injury CNS-specificity Elevated blood GFAP  
levels to predict TBI outcome 
Vos et al.,  
2010 [48] 
GFAP breakdown products (GFAP-BDP) Glia cells 
Specific marker of brain damage GFAPBDP >0.68 lg/L  
within 24 h of injury was associated with acute traumatic lesions on 
the CT and with unfavorable 6-month outcome 
Okonkwo et al., 
2013 [49] 
Angiopoietins-1/2(Ang-1/2) Endothelia cells 
Vascular injury and regeneration evaluation in plasma,  
serum and cerebrospinal fluid 
Chittiboina et al., 
2013 [50] 
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3.4. Clinical Limitations and Outlook 
Though numerous candidate biomarkers have proven a positive association with TBI outcome,  
they showed low specificity or sensitivity when used individually. Combining biomarkers into a panel 
may provide more information than individual biomarkers [51]. In a study of 206 subjects, GFAP  
and UCH-L1 together had better sensitivity and specificity to discriminate between TBI patients and 
healthy controls than either biomarker alone. The combination also had better sensitivity and 
specificity for predicting 3-month outcomes [52]. Other combinations of biomarkers found to have 
prognostic value for TBI outcomes include GFAP, UCH-L1, SBDP145 [53], NSE, and s100b [51,54]. 
The progressive increase in TBI brings with it more variable and complex long-term neurological 
disorders. The heterogenetic and multifactorial nature of secondary responses in TBI make it difficult 
to find cellular biomarkers for diagnosis, prognosis and management of TBI. It is imperative to find 
more accurate TBI-specific markers to take the place of CNS-restricted markers. Systems biology 
strategies can be applied to probe and analyze the crosstalk between different molecular signaling 
pathways that regulate the secondary cellular response through computational models, which integrate 
the diverse data sets. Feala and colleagues described opportunities for applying this methodology to 
existing TBI data sets to identify new biomarker candidates and gain insights about the underlying 
molecular mechanisms of TBI response. For instance, they manually compiled a list of 32 protein 
biomarker candidates from the literature, and then applied network and pathway analysis to recover 
known TBI-associated mechanisms and produce new hypothetical biomarker candidates. The 
combination of neuroproteomics with systems biology and other molecular biology techniques will be 
ideal tools for discovering well-validated TBI-specific biomarkers [55]. 
Although great progress has been made with the aid of advanced technologies, the need for 
transitioning from research-based experimental screening with mass spectrometry to fast and reliable 
diagnostic instrumentation is imperative for the use of biomarkers in the clinical setting. 
4. Neuroimaging Advances for TBI Diagnosis and Prognosis 
The essential aims of neuroimaging after TBI are to assist in prevention of secondary damage,  
to emphasize favorable biomarkers with potential for neurodegenerative disease detection, and to 
obtain prognostic information about long-term outcome. Neuroimaging methods such as computerized 
tomography (CT) and magnetic resonance imaging (MRI) which are identified as conventional 
neuroimaging techniques and are generally used for the initial clinical evaluation and acute vital 
management of intracranial problems following TBI [56]. CT is generally the imaging modality of 
choice for initial screening in order to exclude serious intracranial injury and provide an early 
assessment of the extent of brain injury [57]. MRI is indicated in acute TBI when neurologic 
examination is not consistent with CT findings and provides more sensitivity with detection of white 
matter abnormalities [58]. 
Diffuse axonal injury (DAI) determines long-term cognitive and neuropsychiatric outcomes 
following mild TBI, both hemorrhagic and non-hemorrhagic. Shearing axonal lesions are located in the 
major white matter tracts, spreading from the surface to deeper structures [59]; however, conventional 
neuroimaging methods are insensitive to DAI. 
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Advanced structural neuroimaging techniques are susceptibility-weighted-imaging (SWI),  
diffusion-weighted-imaging (DWI), diffusion-tensor-imaging (DTI) and high-definition-fiber-tractography 
(HDFT). Advanced functional neuroimaging methods include MR spectroscopy, functional MR 
imaging, SPECT and magnetoencephalography [56]. 
These techniques are beneficial for finding abnormalities in the brain related to long-term traumatic 
sequelae and the focus of ongoing research is to identify structural and functional correlations while 
analyzing fiber tracts [60]. The American Journal of Radiology in 2015 concurred that advanced 
neuroimaging techniques show promising results in group comparison analyses; however, there is still 
lack of evidence supporting the routine clinical use of advanced neuroimaging for diagnosis and/or 
prognostication at the individual patient level [61]. 
Listed below (Table 3) are the advanced structural and functional neuroimaging techniques and 
their association with main clinical applications and limitations. 
Table 3. Neuroimaging. 
Neuroimaging Techniques Attributes Limitation 
Susceptibility-weighted 
imaging (SWI) 
Microbleeding in diffuse 
axonal injury 
Long acquisition time and  
sensitivity to motion artifacts 
Diffusion-weighted  
imaging (DWI) 
Non hemorrhagic diffuse 
axonal injury 
Heterogeneity with large standard  
deviation of the ADC changes 
Diffusion tensor  
imaging (DTI) 
White matter integrity 
FA measurement is compromised  
by interstitial fluid content 
High definition fiber 
tractography (HDFT) 
Structural brain connectivity 
Restricted ability to determine  
crossing of fibers within a voxel 
Functional MRI (fMRI) 
Neuronal activity with cerebral 
oxygen consumption 
Physics based factors of signal and the field 
inhomogeneity generated by deoxyhemoglobin 
Magnetoencephalography 
(MEG) 
Magnetic fields of 
postsynaptic ionic currents 
Variety of incomparable approaches and  
absence of standard analyzing protocols  
Magnetic resonance 
spectroscopy (MRS) 
Intracellular neuronal 
metabolic status 
Limited spatiotemporal resolution and  
small brain fields are challenging to analyze 
Single-photon emission 
computed tomography (SPECT) 
Regional cerebral blood flow 
Regional cerebral blood flow changes after  
TBI do not always correspond to metabolism 
4.1. Susceptibility-Weighted Imaging (SWI) 
Susceptibility-Weighted Imaging (SWI) combines both magnitude and phase data to increase  
the contrast between hemorrhage-related blood products and the surrounding brain parenchyma, 
thereby allowing usefulness in detection of small amounts of altered blood and blood products on 
neuroimaging [62]. Glushakova and colleagues conducted an experimental TBI study about 
pathophysiological cascades, including microvascular damage and inflammation which indicated that 
the development of focal microbleeds was associated with delayed and localized brain blood barrier 
(BBB) breakdown, as well as progressive degeneration of white matter up to 3 months following 
injury. Delayed white matter damage and development of focal microbleeds were co-localized with 
cellular markers of regional inflammation [63,64]. An important advantage of SWI is the detection of 
microbleeding, as it suggests the presence of diffuse axonal injury and is not seen on conventional 
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MRI [65]. Hemorrhagic lesions illustrate shear injury to small vessels and are thought to be a marker 
of axonal damage, but MRI may more directly reflect axonal damage of non-hemorrhagic white matter 
foci after TBI [66]. SWI is capable of visualizing venous blood vessel continuity, and is six times more 
sensitive than conventional MRI for detecting diffuse axonal injuries [67], and microbleeds. Furthermore, 
the total amount, volume, and extent of SWI-identified microbleeds correlate with initial Glasgow Coma 
Scale scores, duration of coma, and long-term outcomes measured at 6–12 months after injury [68]. 
A study by Ryan and colleagues aimed to investigate the utility of SWI as a biomarker for 
prediction of outcome and recovery of social cognition after pediatric TBI, and concluded that SWI in 
the acute phase of injury may be a useful indicator of not just the severity of brain injury, but may also 
assist clinicians to identify children at elevated risk for poor social cognitive function in the post-acute 
recovery period [69]. 
Shaken baby syndrome, now called abusive head trauma [70] have great benefits from a variety of 
imaging techniques. Even though studies have proposed that clinical and histological proof of this 
condition are related to hypoxic–ischemic injury, diffuse axonal damage seems to be an important 
factor [71]. Gleckman and colleagues described DAI to be the reason for mortality in almost all of 
their studied abusive head trauma victims [72]. Additionally, Niwa T. and collegues reported 
hemorrhage detection in cortical laminar necrosis with SWI due to the same syndrome [73]. This 
condition can have cerebral ischemia manifestation acutely as one of the essential parameters to its 
diagnosis, making DWI an extremely useful technique, as confirmed by Biousse V. and collegues in a 
study that showed DWI abnormalities in patients with the same diagnosis. These abnormalities were 
either diffuse or predominantly in the distribution of the posterior watershed territories [74]. 
Earlier studies that used MRI imaging to detect traumatic microbleeding failed to demonstrate 
correlation with functional outcomes [75]. SWI enabled improvements in outcome prediction in 
lesions that have a particularly high prognostic significance. Magnetic field strength, in-plane spatial 
resolution, and the distance between adjacent slices [76] may significantly affect the number of 
observable microbleeds, as higher spatial resolution increases microbleeding detection [77]. 
Wang Xuan and colleagues studied SWI combined with conventional MRI and CT images to 
prospectively analyze mild TBI patients 1 year post TBI. Their results showed SWI detected 
microbleeds that went undetected on conventional MRI and CT images. Microbleed lesions detected 
by SWI on the frontal, parietal, and temporal lobes may correlate with higher incidence of depression 
after TBI [66]. 
4.2. Diffusion-Weighted Imaging (DWI) 
Diffusion-Weighted Imaging (DWI) with its known functions such as measuring patterns of water 
diffusion based on surrounding temperature, structures, and tissue damage [78]. Areas with a high 
degree of diffusion such as the cerebrospinal fluid will be hypointense on DWI and display a high 
ADC value [79]. Areas where diffusion is restricted due to the presence of swollen ischemic cells in 
acute diffuse axonal injury lesions appear hyperintense on DWI and display low ADC value [80]. 
Water diffusion develops over an uncertain timeline in traumatic axonal injury, likely due to the 
variable pathophysiological changes that occur in the intracellular compartment and may persist up to 
18 days after TBI [77]. Cytotoxic edema is associated with cellular swelling by decreasing 
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extracellular fluid and leads to intramyelinic accumulation of water, producing myelin edema [81].  
In contrast, vasogenic edema is caused by increased permeability of the blood–brain barrier as well  
as water diffusion [82]. Unlike SWI, DWI has the ability to explain the pathophysiology of  
non-hemorrhagic diffuse axonal injury. White matter apparent diffusion coefficient is particularly 
useful for predicting outcomes [83], as it was demonstrated that values of diffusion in the white matter 
and in the corpus callosum correlate with functional outcomes in severe TBI patients at the time of 
hospital discharge [84]. 
Reduced ADC values in the corticospinal tracts and corpus callosum have also been observed in 
concussed athletes compared to controls. Galloway and colleagues attempted to predict TBI outcomes 
using DWI and reported that apparent diffusion coefficient values of both specific regions and the 
entire brain could be used as an outcome predictor in pediatric cases of severe TBI [85]. Hudak and 
colleagues conducted a clinical trial regarding connections between types of edema with DWI and 
prognosis, and reported that the cytotoxic edema group had more severe injuries and acute signs of 
clinical impairment when compared to participants with predominantly vasogenic edema, despite the 
fact that both cytotoxic and vasogenic edema groups reached a similar level of functional recovery by 
6 months post-injury [86]. In an experimental TBI model in rabbits, decreased ADC values during the 
acute phase in the focal lesion area correlated with poor functional outcomes at 30 days. This suggests 
these values are associated with the extent of brain damage and have predictive value [81,82].  
Non-hemorrhagic lesion load detected in the acute setting by DWI is a significant parameter, and 
Moen and colleagues demonstrated that the number of DWI lesions in the corpus callosum and brain 
stem significantly predicted outcomes for patients with severe TBI in multi-variable analyses. In 
addition, they investigated possible traumatic axonal injury in normal-appearing corpus callosum and 
its effect on outcomes. No differences between TBI patients and healthy control subjects were found. 
A special finding by Moen and colleagues was that the mean ADC values of the normal-appearing 
corpus callosum had a wide variation in the early stages, as the patient group had both very low and 
high ADC values, explained by the reflecting differences in pathology of injury [87]. 
In the early stages of TBI, diffusion of water molecules can be affected by axotomy and myelin 
degradation associated not only with increased ADC values but also post-traumatic cytotoxic edema 
with reduced ADC values [88,89]. The balance between cytotoxic and vasogenic edema generates  
a wide range of ADC values [90]. 
The fact that ADC values are high in the subacute phase indicates a massive increase in the 
extracellular water content of the tissue, reflecting the progressive loss of proteins in the extracellular 
matrix combined with cellular degeneration and increased diffusion of water molecules [91,92]. 
Håberg and colleagues correlated the extent of vasogenic brain edema with high ADC values in the 
perifocal lesion area caused by BBB breakdown [93]. Continuously higher ADC values following TBI 
is associated with persistent injury in the perifocal lesion area. However, partial recovery of ADC 
values in the perifocal lesion area during the subacute phase might be detected and explains how the 
complexity of physiological and molecular interactions affect their values [94]. Although DWI has 
important benefits in identifying axonal injury induced by trauma, the disadvantages of spatial 
resolution of current diffusion imaging methods and their sensitivity to signal loss from edema and 
hemorrhage make it difficult to visualize the specific locations of axonal injury and isolate the affected 
pathways. Maegele and colleagues conducted a study with experimental TBI in the acute (6 h), 
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subacute (48 h), and chronic phase (7 days) in rats by DWI and ADC mapping and correlated these 
results with ATP-specific bioluminescence imaging and histology. They reported no homogeneous 
area of ADC alteration between both hemispheres in any of the selected regions and also extreme ADC 
heterogeneity with large standard deviation of the ADC changes in all regions studied. In some cases, 
variable ADC values in neighboring slices of the same animal were detected. This leads us to conclude 
that the heterogeneous ADC patterns provides a mixed expression of vasogenic and cytotoxic edema 
following TBI [95]. 
4.3. Diffusion Tensor Imaging (DTI) 
Diffusion imaging methods have clinically influenced the improvement of TBI as a result of their 
ability to detect the effects of injury upon white matter structural integrity [96]. Diffusion tensor 
imaging (DTI), an extension of DWI, measures diffusion of water molecules within the white matter of 
the brain [97]. Apparent diffusion coefficient (ADC) or mean diffusivity (MD) describes a measure of 
the rate of diffusion of water molecules, which is usually averaged over all directions. Their values are 
similar when obtained from the same scanner. High fractional anisotropy (FA) and low ADC/MD 
values indicate that the cortical white matter tracts are intact; low FA and high ADC/MD values 
indicate that a nerve fiber is injured [98]. In pathological states such as edema, axonal degeneration, 
demyelination or fiber disruption, the diffusion of water along the direction of the nerve microstructure 
is affected and the amount of water diffusion increases as there are fewer intact structures binding 
water molecules, leading to a decrease in fractional anisotropy because of restricted axoplasmic flow 
and increased flow across the axonal membrane [99]. 
Hberg and colleagues in 2014 conducted a detailed clinical research study with 78 healthy and 73 
chronic TBI patients. He outlined not only injury mechanisms, but also neuroimaging and clinical 
measures from the acute and early phases after injury and its impact on white matter FA, MD, and tract 
volumes in the chronic phase of TBI, and how white matter integrity in the chronic phase is associated 
with different outcome measures. They concluded that FA was the primary determinant of injury 
severity and mechanism, and diffuse axonal injury of any grade led to lower FA in the thalamus and 
brainstem. Minor effects on MD were observed in severe TBI associated with low cerebral perfusion 
pressure (below 70 mmHg). 
Studies have shown FA several standard deviations below a control group average reflects the 
number of regions with “abnormally” low white matter integrity, and correlates with measures of 
trauma severity and cognitive dysfunction [100]. A number of areas with affected white matter, rather 
than the magnitude of damage within any single region, appears as the most important aspect of the 
brain damage associated with TBI. This is due to the specific regions of exposed white matter integrity 
diversified across individuals [101]. 
FA has been proposed as the most feasible biomarker of traumatic axonal injury and one of the best 
indicators of TBI severity. The most powerful applications of DTI techniques involves the specific analysis 
of particular regions of interest which are selected based on known or suspected tendency to demonstrate  
a particular pathological state [102]. In addition, sports-related mild TBI studies in older adolescents and 
young adults in the post-acute period [103,104] and adult mild TBI outcome studies [105] show consistent 
findings. Roberts and colleagues reported a meta-analysis on 20 studies in non-penetrating pediatric 
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TBI and concluded a decrease in the integrity of white matter microstructure occurs three or more months 
after mild to severe pediatric TBI, and supported DTI as providing a useful biomarker of injury [106]. Most 
DTI analyses show a loss of structural integrity in acute symptomatic TBI patients who presented 
decreased FA values in widespread regions, especially located in frontal lobe, limbic system, and sublobar 
areas compared with healthy controls [107]. In a cohort of 30 adults admitted for neurorehabilitation, 
Sidaros and colleagues found that FA was decreased globally in the white matter of patients compared to 
controls, and the cerebral peduncle FA correlated with the Glasgow outcome score at 1 year following 
injury [108]. Messe and colleagues using DTI, showed a statistically significant difference in mean 
diffusivity within the long association white matter tracts between patients with good and poor outcomes 
based on their symptoms [109]. Dodd and colleagues reported a meta-analysis on 31 studies published 
from 2002 to 2013 assessing white matter injury during the acute/semi-acute phase of mTBI, and DTI 
results show decreased FA in chronic TBI and in more severely injured TBI cohorts. Mixed findings were 
found in the semi-acute (less than 3 months post-injury) phase of mTBI. Multiple inflammation 
mechanisms might potentially explain these diffusion variations in DTI [110]. Cubon and colleagues 
suggested that mean diffusivity (MD) may be more sensitive than FA to effects of mTBI [111]. However, 
Davenport and colleagues did not detect any result indicating greater sensitivity for FA than MD [112]. 
4.4. High Definition Fiber Tractography (HDFT) 
High Definition Fiber Tractography (HDFT), tracks fibers from the cortex to subcortical targets 
with high resolution [113]. It also reveals more than 250,000 fibers with 256 possible directions, 
enabling it to project complex 3D anatomies and superior resolution of the white matter compared with 
standard DTI [97,114]. 
HDFT applies diffusion spectrum imaging, which has a high angular resolution than release 
tractography to navigate complex fiber crossings. Thus, HDFT provides high-resolution details of axonal 
pathways and projection fields that allow exposure of specific location and degree of damage [85]. Shin 
and colleagues reported a use of HDFT to identify white matter damage following TBI in a case where a 
32-year-old man sustained a severe TBI with Glasgow Coma Scale score of 6 and left/right asymmetries. 
They identified a specific lesion of the corticospinal pathway in the corona radiata that was precisely 
correlated with the functional deficits. The volumetric losses as well as the number of fibers projecting 
from the motor cortices were diminished in the injured side, corresponding to the left upper-extremity 
weakness. In addition, despite basal ganglia hemorrhage present on imaging methods such as CT, structural 
MRI, and DTI, the patient’s hemiplegia could not be entirely explained by basal ganglia damage. With 
HDFT, they specified lesions in the corticospinal pathway adjacent to the basal ganglia and quantified the 
extent beyond the capabilities of other neuroimaging modalities, which suggested damage in the posterior 
limb of the internal capsule. Due to analysis of HDFT outcomes, high-resolution white matter imaging and 
comparisons of left/right fiber tractography supports significant diagnostic information in characterizing the 
nature of motor pathologies [115]. 
4.5. Functional MRI (fMRI) 
Functional MRI (fMRI) assesses brain function based on relations between neuronal activity and  
the resultant hemodynamic responses described as neurovascular coupling [116,117]. fMRI studies 
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generally focus on not only cognitive and behavioral sequelae of TBI but also episodic memory 
circuitry activation after trauma, post-traumatic stress disorder, and major depressive disorder 
following blast injury [118]. Functional deficits in speeded information processing and attention can be 
detected after frontal lobe damage following TBI [119]. 
fMRI is usually performed while the patient completes a neurocognitive task, placing an increased 
demand on the brain, thus showing differences in local perfusion in real time. Abnormal brain activation 
patterns detected by fMRI correlate with a broad range of neurocognitive and functional deficits in patients 
with prior traumatic coma, including memory impairment and motor dysfunction [120]. In a cohort of 
adolescents with chronic moderate-to-severe TBI, patients performing a perspective-taking task exhibited 
BOLD signal changes in regions such as the cuneus and parahippocampal gyrus that were not observed  
in controls. Differential fMRI brain activation patterns were present despite the fact that patients  
exhibited normal performance scores on neurocognitive tests [121]. These results suggest that recovery of 
neurocognitive function might concern the enrollment of additional neuroanatomic connections [122]. 
Positive correlations between self-reported measures of symptom severity and increased activation of both 
dorsolateral and ventrolateral prefrontal cortex suggests potential compensatory activation [123]. Talavage 
at al., conducted an evoked fMRI study that also utilized a pre- vs. post-injury design in athletes. Their 
results indicated that prolonged exposure to sub-concussive hits resulted in hypoactivation within the left 
middle and superior temporal gyri, left middle occipital gyrus, and bilateral cerebellum during a working 
memory task, which correlated with decreased working memory performance in the non-concussed high 
school football players [124]. 
Resting-state fMRI (RS-fMRI), a recent form of fMRI, is based on the analysis of spontaneous  
low-frequency fluctuations in the BOLD signal in the absence of any external task. Thereby, it focuses 
on functionally related brain regions at rest [125]. One of the most studied resting state brain networks 
is the default mode network (DMN) [126]. DMN describes a state of consciousness in which an 
individual is awake and alert, but not actively participating in any cognitive or functional tasks [127]. 
Nathan and colleagues designed a descriptive study that aimed to understand how functional 
connectivity of the resting state DMN varies between healthy controls and mTBI subjects differs.  
They reported that mTBI patients had a decrease in DMN connectivity within regions of the left 
inferior temporal lobe, right precentral gyrus, and left caudate nucleus. They also demonstrated 
significant correlations between a variety of neuropsychological test measures and data from DMN 
connectivity maps of TBI subjects in cerebellar and cortical regions. Their results show the ability to 
correlate markers of emotional response within the cerebellum. fMRI is sensitive to changes in neural 
function following TBI and is an effective technique for understanding the neural basis of  
cognitive-behavioral dysfunction and investigating recovery of function [128]. 
4.6. Magnetoencephalography (MEG) 
Magnetoencephalography (MEG) detects magnetic fields generated by currents flowing in neurons 
through a group of sensors surrounding the head [129,130]. Abnormal delta-waves emerge from 
deafferentation of neurons following traumatic axonal injury in brain tissues after TBI to the white matter 
fiber tracts, as demonstrated on diffusion tensor imaging with reduced fractional anisotropy [131]. The 
patient repeatedly performs tasks such as auditory, visual, tactile or electrical stimuli while MEG detector 
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documents the brain activity [132]. MEG can examine neuronal change and reorganization during normal 
interactions between different brain regions as exemplified in language processing [133] or abnormal 
connections between multiple suspected epileptogenic regions following TBI [134]. 
Huang and colleagues detected sensitivity of MEG for analyzing resting-state MEG data and found 
abnormal delta-waves in 84.5% for all mild and symptomatic TBI patients [135]. Multiple regions in 
the frontal lobe, posterior parietal lobe, inferior temporal lobes, hippocampus, and cerebellum have  
a relatively higher likelihood for generating abnormal MEG slow-waves than other brain areas, 
indicating that these regions are also particularly vulnerable to head trauma [131]. A recent MEG study 
in a group mixing mild, moderate, and severe TBI patients showed reduced functional connectivity 
primarily in bilateral frontal regions with left parieto-temporo-occipital regions greater than right [136]. 
The role of MEG in diagnosis and prognosis is still limited because of the variety of incomparable 
approaches and absence of standard protocols for MEG analysis. MEG applications require 
improvements before becoming clinically relevant. More studies are needed to examine the utility of 
MEG as a prognostic and predictive neuroimaging method for TBI. 
4.7. Magnetic Resonance Spectroscopy (MRS) 
Magnetic Resonance Spectroscopy (MRS), a molecular-based neuroimaging technique that reflects 
intracellular metabolic status as evidence of microscopic injury [137]. Common neuronal markers 
utilized during MRS include: N-acetylaspartate (NAA), a neuronal mitochondrial marker that 
decreases with neuronal loss or dysfunction; creatine (Cr), a marker for intact brain energy 
metabolism; and choline (Cho), a marker for membrane disruption, synthesis or repair. Increasing 
amounts of Cho detected in white matter is a breakdown product after myelin damage [138]. 
Metabolites such as lactate (Lac) (generated as a result of anaerobic glycolysis) and glutamate 
(excitatory amino transmitter) might suggest evidence of energy dysfunction, membrane turnover, and 
inflammation as a result of injury [139]. The relative concentrations of metabolites are described as an 
array of peaks along a spectrum; abnormal ratios between the peaks prove metabolic dysfunction following 
TBI. Neuronal metabolites measured with MRS allows direct detection of the brain region of interest [61]. 
Harris and colleagues conducted an experimental rat study to describe neurometabolic effects of TBI using 
high field MRS. They reported alterations of 20 metabolites in the rat brain following TBI. MRS scans 
were performed 2 weeks before TBI and up to 14 days after TBI. Functional deficits, lesion characteristics, 
and neurochemical profiles of TBI in contused and normal-appearing brain regions were evaluated. 
Neurometabolic changes at the cortical contusion site included fourteen neurochemicals significantly 
decreased and five (Gln, PCho, Lac, Ala, and Ser) increased after TBI [140]. 
Various studies indicate that NAA levels and NAA/creatinine ratios are reduced in TBI as a result of 
neuronal loss and/or dysfunction. Reduced NAA levels are predictive of long-term functional outcomes in 
TBI. Twelve athletes who had sustained sports-related concussions were compared with healthy controls 
within 6 days of injury. The NAA/Cr levels were significantly reduced in the primary motor cortex and, to 
a lesser extent, in the dorsolateral prefrontal cortex when compared to healthy controls [141]. Sports-related 
concussions and NAA/Cr relationships were studied by Vagnozzi and colleagues in 14 sports related 
concussed athletes. MRS was performed at 3 to 4 days, 15 days, and 30 days after injury. Decreased 
NAA/Cr ratio was detected at 3 to 4 days following concussion and limited recovery was seen at 15 days 
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post-injury. NAA/Cr ratio was within a normal range at 30 days postinjury. Despite abnormal MRS 
findings, postconcussive symptoms resolved at 3 days following TBI [142]. Maudsley and colleagues 
studied 40 closed-head TBI patients who underwent DTI and MRS. Changes of both DTI and MRS 
following TBI are widely distributed and predominate across white-matter regions, with the metabolic 
changes seen on MRS covering a wider spatial extent than those seen in the DTI. These changes also 
reflect different aspects of the injury, considering extensive metabolic changes can be seen despite absence 
of measured DTI changes [143]. Tollard and colleagues performed MRS on 43 patients 24 days post TBI. 
The study aimed to predict functional outcomes at one year. They found that NAA/Cr ratios-specifically in 
the pons, thalamus, and insula-predicted an unfavorable 1-year outcome with 75% sensitivity and 75% 
specificity. Furthermore, when MRS was combined with DTI measurements, the combined predictive 
value of MRS and DTI for unfavorable outcome increased to 86% sensitivity and 97% specificity [144]. 
Govind and colleagues conducted a study during the subacute period following TBI. They studied 
not only the associations of metabolite indices with neuropsychological test results, but also 
differences in metabolite ratio distributions. Hemispheric lobes and tissue types were evaluated relative 
to those of age-matched controls. Significant metabolite alterations were present in locations remote 
from, or in the absence of any MRI-observed traumatic lesions, and significant correlations were found 
between metabolite measures [143]. 
4.8. Single-Photon Emission Computed Tomography (SPECT) 
Brain perfusion single-photon emission computed tomography (SPECT) imaging is a functional 
nuclear imaging technique performed to assess regional cerebral perfusion by using 99 mTc ethyl 
cysteinate diethylester (ECD) as tracer [145]. 
SPECT scans can display areas of impaired brain function following TBI including not only focal 
cerebral blood flow (CBF) reduction near the focal site of injury, but also asymmetrical hypoperfusion 
in the prefrontal, temporal, and parietal or occipital lobes. In addition, a decreased CBF in the anterior 
temporal poles was observed [146,147]. SPECT discloses regions of hypoperfusion correlated with 
severity of acute injury, loss of consciousness, cognitive deficit, and brain atrophy [148]. 
Some early studies compared the value of CBF SPECT imaging to anatomical findings on MRI or 
CT in TBI patients. Ichise and colleagues [146] conducted a correlational study and reported that 
SPECT imaging was able to detect abnormalities in 66% of patients who had chronic symptoms 
following TBI, whereas MRI and CT did so in 45% and 34% of 29 patients, respectively [146]. Similarly, 
Kant and colleagues reported abnormal SPECT scans in 53% of patients, while MRI and CT detected 9% 
and 5% of 43 patients with persistent post-concussive symptoms, respectively [149]. Newberg and 
colleagues have demonstrated significant cerebral blood flow differences in right frontal lobe, and left 
parietal lobe of patients who reported headaches post-TBI [150]. Jacobs and colleagues prospectively 
evaluated 67 TBI patients who had SPECT scan within four weeks of the initial injury and three months 
after the first scan. Of those, 33 patients showed no significant abnormalities on their initial SPECT scan 
and 97% experienced positive outcomes in their clinical symptoms within three months following TBI. 
They found 34 patients with pathologic initial SPECT scans, and 59% of these patients continued to 
encounter notable clinical symptoms at 3 months follow up. At 12 months following TBI, pathologic 
SPECT scans were found to have increased sensitivity up to 95% [151]. Romero and colleagues designed  
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a study aiming to correlate cerebral perfusion changes in TBI patients with depressive symptoms. They 
reported that mild levels of depressive symptoms following mild TBI do not contribute to subacute cerebral 
hypoperfusion, as quantified measures of SPECT perfusion were unable to distinguish among mild TBI 
patients regarding the presence of depressive symptoms [152]. 
SPECT can detect brain activation changes during complex cognitive tasks in patients with chronic 
symptoms following TBI [153]. Hattori and colleagues observed a pattern of activation in TBI patients 
different from that in healthy control subjects. Patients with mild TBI presented with less activation in the 
cerebellum despite relatively more activation in the prefrontal cortex. They demonstrated functional 
frontocerebellar dissociation because of possibly impaired connection fibers due to axonal injury or 
degeneration after TBI. These findings were hypothesized to exist due to a mechanism of  
compensation [154]. Because of the diffuse nature of TBI, post-injury regional cerebral blood flow is not 
always proportionate with metabolism in SPECT, despite its good correlation in healthy individuals [155]. 
5. Neuromonitoring after TBI 
During the last decades, multimodal neuromonitoring technology has made great progress. It has 
been shown to play an important role in treatment of TBI, preventing secondary brain injury and 
promoting better patient outcome. 
5.1. Intracranial Pressure (ICP) Monitoring and Cerebral Autoregulation 
Continuous intracranial pressure (ICP) monitoring is widely used clinically after severe TBI. 
Although clinical studies in ICP monitoring overall showed controversial results, recent trials indicate 
lower mortality and better outcome in patients with monitored and controlled ICP. The Brain Trauma 
Foundation recommends with level II evidence to treat ICP above 20 mmHg [156–161]. 
Two established invasive methods are the application of an intraparenchymal microsensor and  
the intraventricular catheter. The intraventricular catheter is considered the gold standard, since it 
measures global ICP and allows drainage of cerebrospinal fluid as treatment or administration of drugs. 
Intraparenchymal ICP monitors, on the other hand, are frequently used as a first-line monitoring method 
and are considered to be safe and of equal accuracy to intraventricular measurements [162–164]. Devices 
have been developed offering the ability to monitor ICP and parenchymal temperature. Treatment 
based on ICP monitoring alone may not be enough in the complex heterogenic entity of TBI. Several 
studies showed that treatment based on multimodal monitoring is superior to ICP alone. This induces 
investigation of further indices and factors with better correlation to mortality and outcome [157,165]. 
ICP is frequently used in TBI treatment to calculate the cerebral perfusion pressure (CPP) involving 
the patient’s mean arterial pressure. With level II and III evidence the Brain Trauma Foundation 
recommends to maintain a CPP threshold between 50 and 70 mmHg [160,162]. ICP pulse-wave-patterns 
have been a research topic focusing on computerized analysis of morphological changes of ICP waves. 
Recently an algorithm has been introduced as Morphological Cluster and Analysis of Intracranial 
Pressure (MOCAIP) that might offer a promising way to measure cerebral perfusion and detect  
real-time cerebral hypoperfusion [166]. 
The future in monitoring seeks for noninvasive methods with equal accuracy as invasive techniques. 
Neuroimaging, as described in the previous section, can be considered as noninvasive single point of 
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time of ICP evaluation. Recent studies showed possible ICP estimation by measuring the optic sheath 
diameter using ultrasound [167] or magnetic resonance imaging [163,168,169]. 
Cerebral autoregulation stands for the regulation of the cerebral blood flow by dilation and 
constriction of cerebral arterioles in response to changes of cerebral perfusion pressure. In neurocritical 
patients a dysregulated autoregulation of pressure flow or reactivity has been linked to poor outcome. 
Developing the best correlating monitoring coefficient for tailored treatment and prognosis is a central 
research topic in TBI [170]. 
Currently known indices using further monitoring methods with promising results are shown in 
Table 4, involving data derived from additional methods like transcranial Doppler, NIRS or 
measurement of brain tissue oxygen. 
Table 4. Indices of cerebral autoregulation. 
Index Reference Title 
PRx (pressure reactivity index) Howells et al., 2014 [171] 
An optimal frequency range for assessing the pressure reactivity 
index in patients with traumatic brain injury 
L-PRx (low-frequency  
pressure reactivity index) 
Depreitere et al., 2014 [172] 
Pressure autoregulation monitoring and cerebral perfusion pressure 
target recommendation in patients with severe traumatic brain 
injury based on minute-by-minute monitoring data 
Mx (mean index, TCD-derived) Zweifel et al., 2008 [173] 
Continuous monitoring of cerebrovascular pressure  
reactivity in patients with head injury 
Sx (systolic flow index,  
TCD-derived) 
Budohoski et al., 2012 [174] 
Monitoring cerebral autoregulation after head injury. Which 
component of transcranial Doppler flow velocity is optimal 
PAx (pressure-amplitude index, 
TCD-derived) 
Radolovich et al., 2011 [175] 
Pulsatile intracranial pressure and cerebral  
autoregulation after traumatic brain injury 
PI (pulsatility index,  
TCD-derived) 
Melo et al., 2011 [176] 
Transcranial Doppler can predict intracranial hypertension in 
children with severe traumatic brain injuries 
COx (cerebral oximetry index, 
NIRS-derived, Somanetics) 
Brady et al., 2007 [177] 
Continuous time-domain analysis of cerebrovascular 
autoregulation using NIRS 
TOx (tissue oxygenation index, 
NIRS-derived, Hämamatsu) 
Steiner et al., 2009 [178] NIRS can monitor dynamic cerebral autoregulation in adults 
HVx (haemoglobin volume 
index, NIRS-derived, 
Somanetics) 
Lee et al., 2012 [179] 
Noninvasive autoregulation monitoring in a  
swine model of pediatric cardiac arrest 
THx (total haemoglobin 
reactivity index,  
IRS-derived, Hämamatsu) 
Zweifel et al., 2010 [180] 
Noninvasive monitoring of cerebrovascular  
reactivity with NIRS in head-injured patients 
ORx (brain tissue oxygen 
reactivity index) 
Lang et al., 2014 [181] 
Changes in cerebral partial oxygen pressure and cerebrovascular 
reactivity during intracranial pressure plateau waves 
Abbrev.: TCD = Transcranial Doppler. 
5.2. Brain Oxygen Monitoring 
In 2007, brain oxygen monitoring was added into the Brain Trauma Foundation guidelines with a 
level III evidence to treat brain tissue oxygen tension thresholds below 15 mmHg. In the past decade 
several studies showed a correlation between low brain oxygen levels and higher mortality rate and 
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unfavorable outcome [182,183]. Combined monitoring of ICP and brain tissue oxygen tension has 
shown to be superior to ICP alone [184,185]. Additionally, brain oxygenation offers a new variable  
to evaluate cerebral autoregulation and cerebrovascular reactivity as mentioned before in Table 3.  
There are measuring devices with two different techniques to monitor the partial oxygen pressure in 
the surrounding brain tissue offering simultaneous monitoring of partial carbon dioxide pressure, 
temperature and ICP. The Licox microcatheter is the most frequently used in clinical settings and is 
based on the Clark principle, a polarographic technique. The Neurovent-PTO sondes are optical 
technique based, the same as the OxyLite catheter that is only used under experimental condition. 
Unfortunately values measured with different sensors cannot be compared directly [186]. In the 
management of patients with TBI the use of Licox has been demonstrated in several trials to improve 
outcome [184]. Neurovent has shown promising results in initial studies of clinical cases [187]. 
A non-invasive way to assess real-time regional cortical oxygenation is with NIRS (near-infrared 
spectroscopy). It is most frequently used in cardiovascular surgery to detect cerebral oxygenation 
changes during surgical cardiac arrest during cardiopulmonary bypass. NIRS is non-invasive, but has a 
number of limitations causing highly variable results and, therefore, is only used for restricted 
indications [183]. Track changes may be monitored with this method, and a baseline for comparison is 
needed. In case of TBI, brain tissue oxygenation may be already compromised from the beginning and 
an absolute measurement is necessary for evaluation [188]. Recently in a piglet model with controlled 
reduction of arterial blood pressure, NIRS has shown to be suitable for long-term monitoring of 
cerebral autoregulation and blood flow and high correlation to Laser Doppler Flowmetry [173]. The 
device, CerOx 3110, using NIRS technology, combined with ultrasound, has been introduced as a 
method based on ultrasound-tagged near-infrared spectroscopy (UT-NIRS) to measure regional 
cerebral tissue oxygenation and blood flow. Correlation to jugular bulb venous monitoring could be 
provided for the ipsilateral hemisphere, whereas correlation of Licox and CerOx oxygenation measures 
could not be shown in severe TBI [189]. 
The heterogeneous entity of TBI makes generalizable equations and overall studies difficult.  
Recently a new method for predictive analysis after TBI with symbolic regression modeling has been 
introduced. Symbolic regression was used as a computational framework to study the dynamic 
parameters of ICP, brain temperature and brain tissue oxygen to generate equations from real-time 
data. This may lead to development of dynamic smart monitoring devices that continuously collect 
data and redefine individual critical boundaries with constant improvement of accuracy [190]. 
5.3. Electrophysiologic Monitoring 
Electrophysiology is a well-established non-invasive diagnostic method for neurological 
monitoring, prognostic and follow-up evaluation and also for neuromodulatory therapy after TBI. In 
experimental settings it has been broadly used in models of neurological diseases and in cerebral 
hypoxia and cardiac arrest models [191,192]. In animal models the monitoring of sensory evoked 
potentials was shown to be useful in detecting the course of brain injury and early phases of injury 
progression [193]. 
Especially in mild cases of TBI electrophysiology monitoring proved to be superior to standard 
clinical evaluations only in detecting cerebral dysfunction [194,195]. The analysis of event-related 
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potentials during working memory tasks indicated decreased EEG-wave-amplitudes in patients with 
mild TBI compared to control group [196]. A direct correlation between ICP elevations and durations 
of EEG burst and suppression intervals could be shown. Short periods of electrical activity in EEG of 
burst-suppressed patients were followed by transient ICP elevations. It was suggested in context of 
neurovascular coupling after brain injury [197]. Cortical spreading depolarization is another research 
area as a possible pathophysiological mechanism after TBI. It has demonstrated to have high positive 
and negative predictive value for delayed cerebral ischemia after TBI [198]. 
It should be briefly mentioned at this point, that besides monitoring, EEG may play a role in 
treatment of brain injury. Young TBI-patients showed improvement in cognitive functions and 
concussion symptoms. Additionally, thalamo-cortical connection in follow-up MRI was increased after 
EEG neurofeedback therapy [199]. 
5.4. Microdialysis 
Since the early 1990s, cerebral microdialysis has become an established neurochemical monitoring 
method to analyze low molecular weight biomarkers and to measure metabolic energy crisis or cellular 
distress in brain tissue after injury and ischemia [187,200,201]. The most frequently studied molecules 
are glucose, lactate, pyruvate, glycerol and glutamate (Table 5) [202]. 
Table 5. Clinically used microdialysis biomarkers [203]. 
Marker for Biomarker Clinical Significance 
Energy metabolism Glucose ↓ in hypoxia/ischemia 
 Lactate ↑ in hypoxia/ischemia 
 Pyruvate ↓ in hypoxia/ischemia 
 Lactate/Pyruvate Ratio ↑ in hypoxia/ischemia = best marker for anaerobic metabolism 
Cellular distress Glycerol ↑ with destruction of cell membrane structure and generation of free radicals 
 Glutamate ↑ in hypoxia/ischemia and excitotoxicity 
Treatment of glucose levels measured by microdialysis is controversial. Available data demonstrate 
hyperglycemia is common in TBI patients and is related to poor outcome. However, current clinical 
trials have not proven any benefit of tight cerebral glucose controlled treatment. So far, monitoring of 
cerebral glucose has only proven to detect and predict infarction risk depending on the position of the 
microdialysis catheter [204]. Despite monitoring of brain tissue alone, microdialysis could be used to 
analyze cerebrospinal fluid (CSF) continuously. Microdialysis has demonstrated measurements of  
CSF-glucose and CSF-lactate comparable with conventional laboratory CSF analysis. Elevated  
glucose and lactate levels correlated with poor outcome, although the lactate-pyruvate-ratio has  
been unaffected [205]. 
One cornerstone in intracranial microdialysis research is focused on lactate and the  
lactate-pyruvate-ratio (LPR). Although lactate has been considered to be an excellent biomarker for 
oxygen deprivation, the mechanism of brain lactate metabolism and shuttling remains poorly 
understood in case of TBI [206]. Lactate uptake into the brain appears to be upregulated after TBI to 
potentially serve greater demands for energy substrate [207]. Beneficial effect of exogenous lactate 
infusion on cerebral energy metabolism after TBI is controversial and highly discussed [206,208]. 
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Based on the lactate concentration, the ratio of lactate and pyruvate is a marker for anaerobic cerebral 
metabolism [209]. However, it must be interpreted in consideration of other parameters to distinguish 
between two types of LRP elevations. In cases of low oxygenation due to an ischemic event, LRP is 
elevated in process of anaerobic metabolism. The other type occurs under normal or even high 
oxygenation; LRP may be increased due to activated aerobic hyperglycolysis from deprivation of 
energetic substrates [210]. This phenomenon is called metabolic crisis and is common and deleterious 
after TBI, yet it has not been well studied so far [211]. The following Table 6 shows other promising, 
but less common biomarkers lacking further investigation for evidence of better utility. 
Table 6. Potenial microdialysis biomarkers. 
Biomarker Significance Reference 
Serum albumin BBB disruption Blyth et al., 2009 [212] 
Hemoglobin subunit α and ß Red blood cell degradation Babu et al., 2012 [213] 
Serotransferrin Free iron in the brain tissue Park et al., 2011 [214] 
Creatine kinase B-type Enhancing predictive sensitivity of S100B as a biomarker Bazarian et al., 2006 [215] 
Cystatin C Increased autophagy Liu et al., 2013 [216] 
Apolipoprotein A-1 and E Membrane remodeling due to cellular trauma Mahley et al., 2012 [217] 
α-2-HS-glycoprotein (Fetuin-A) Systemic response to cerebral injury Wang and Sama et al., 2012 [218] 
Complement C3 Activation of the innate immune response to injury Ducruet et al., 2009 [219] 
In stroke models, disruption of ion homeostasis especially in the neurogliovascular unit has shown 
to be pathophysiologically involved in development of cerebral edema and, therefore, increased 
morbidity and mortality after ischemia [220–222]. 
In an experimental TBI model to explore the cerebral ionic profile, microdialysis probes were 
inserted into matrices and perfused with mock cerebrospinal fluid. With this method the actual  
ionic concentration in the extracellular fluid may be calculated based on the concentration in the 
microdialysate [223]. Elevated extracellular brain potassium was shown to be associated with neuronal 
damage in experimental models [224]. A recent pilot study after subarachnoid hemorrhage suggested it 
may serve as a biomarker for secondary brain injury [225]. 
Aiming for technical catheter improvement, a recent paper introduced a surface modified 
microdialysis catheter coated with PluronicF-127. This method have shown promising results in 
improving accuracy and precision of protein biomarker sampling in a porcine brain injury model [226]. 
Overall microdialysis is a promising method to offer sampling and measuring metabolic 
mechanisms, tissue biomarkers and pharmacokinetics in almost any human tissue and organ [227,228]. 
5.5. Brain-on-Chip 
A new innovative technology to monitor changes at the level of axonal and neuronal networks has 
been recently introduced. The brain-on-a-chip device is an experimental strain injury model that 
maintains three dimensional cell architecture. It has been used to visualize hippocampal axonal 
response and biochemical changes induced by diffuse axonal injury after TBI. Changes in the 
mitochondrial membrane potentials have shown to lead to axonal degeneration [229,230]. 
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6. Treatment Strategies and Modalities after TBI 
6.1. Stem Cell Based Therapy 
Stem cell-based therapy has been tested and has been well-documented for years in various disease 
models [231] and especially in stroke research [232]. In this review, we will not elaborate on the 
known mechanisms underlying the therapeutic effectiveness induced by stem cell administration,  
but stress some new concepts and mechanisms to show current updates in the field. Regenerative 
approaches include cell replacement, neurotrophic factor delivery, manipulation of intracellular 
signaling, bridging and artificial substrates, and modulation of the immune response [233]. 
6.1.1. “Biobridges” Paved by Stem Cells 
Tajiri and colleagues proposed a theory of stem cell-paved formation of “biobridges” in 
experimental models of TBI. Rats subjected to TBI were intracerebrally transplanted with SB623 
(gene-modified human mesenchymal stromal cells). One month after TBI, they observed notable 
increases in endogenous cellular proliferation as well as immature neural differentiation in the  
peri-injured cortical areas and subventricular zone, along with a stream of migrating cells along the 
corpus callosum of SB623 transplanted TBI rats. Furthermore, at 3 months post-TBI, they observed 
enhanced cellular proliferation and neural differentiation in peri-injured cortical areas of SB623 
transplanted TBI animals, accompanied by a solid stream of neuronally-labeled cells migrating not 
only along but also across the corpus callosum from the subventricular zone to the impacted cortex. 
TBI rats, which had not received mesenchymal stromal cells, exhibited, elevated cellular proliferation; 
however the newly formed cells were “trapped” within the subventricular zone (SVZ) and cerebral 
cortex and did not migrate to the impacted cerebral cortex. Likewise, these animals showed a 2 and  
9-fold upregulation of the matrix metalloproteinase-9 (MMP) activity and expression, respectively, at 
1 and 3 months post-TBI. MMP-9 was upregulated in the TBI group, but reverted back to sham levels 
at 3 months post-TBI. To provide further evidence that the implanted stromal cells facilitated the 
formation of the biobridge, Tajiri and colleagues used primary rat cortical cells grown both alone and 
co-cultured with stromal cells either in the presence or absence of the MMP-9 inhibitor and revealed, 
by using migratory cell assay, enhanced migration of primary rat cortical cells with stromal cells, while 
these were suppressed by treatment with the MMP-9 inhibitor [234]. 
6.1.2. Stabilized BBB by Stem Cells 
Disruption of the blood brain barrier and vascular neuronal network following TBI often leads to 
uncontrolled inflammation and tissue damage [63,235]. Pati and colleagues designed a study to 
investigate the effects of mesenchymal stem cells (MSCs) on endothelial cells and vascular permeability 
using both in vitro and in vivo experimental methods. MSCs were cocultured with human umbilical 
vascular endothelial cells. At 2 and 24 h after injury MSCs was administered intravenously and rats were 
sacrificed 3 days after TBI. These results showed that MSCs exert a potent stabilizing effect on human 
vascular endothelial cells by increasing VE-cadherin expression and enhanced VE-cadherin/β-catenin 
interaction. Consistent with this, intravenous administration of MSCs increased VE-cadherin levels in 
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brain homogenates and decreased TBI-associated enhanced BBB permeability. In addition, Pati and 
colleagues examined the interaction between tissue inhibitor of matrix metalloproteinase-3 (TIMP3) 
and mesenchymal stem cells due to regulation of blood brain barrier integrity 24 and 72 h post TBI. 
Results showed knockdown of TIMP3 in MSCs fully abrogates the protective effects of these stem 
cells on BBB permeability after TBI by reducing occludin-1 and VE-cadherin expression in the 
penumbra. In addition, following intravenous recombinant TIMP3 (rTIMP3) application after TBI, 
BBB integrity was preserved by increasing the expression of Occludin-1 and VE-Cadherin [236]. 
6.1.3. Reduction of Oxidative Stress by Stem Cells 
TBI consists of a primary insult resulting from a mechanical force inflicted on the head, and is 
amplified by a secondary insult that increases reactive oxygen species (ROS) production, excitatory 
amino acid release, energy consumption, and disturbed calcium homeostasis [237]. Li and colleagues 
have mentioned that in oxidative stress microvascular endothelial cells have an important role in 
redistribution and degradation of tight junction proteins [238]. Torrente and colleagues examined the 
role of hMSC-conditioned medium (hMSC-CM) in scratch-injured glioblastoma cell lines associated 
with metabolic impairment induced by glucose starvation [239]. An increase in wound closure in 
scratched cells treated with increasing hMSC-CM concentrations was observed with increased cell 
viability in glucose-deprived cells at 12 h following stem cell treatment. To assess the effect of 2% 
hMSC-CM in cell morphology, serial pictures were taken by the research group using a bright-field 
microscope and through measuring the distance from the injury site, they found that when cells are 
submitted to both scratch injury and glucose deprivation, hMSC-CM treatment increased cell polarity 
and revealed a higher capability of migration in cells toward injury. They proposed that migration and 
proliferation plays a role in wound regeneration and both processes are acting synergistically, and this 
effect is potentiated by stem cell medium. Due to the fact that increased reactive oxygen species 
production is a common secondary mechanism following brain injury, hMSC-CM administration was 
able to reduce them to basal levels, suggesting their ability to regulate oxidative stress [240]. 
6.1.4. Immunomodulation by Stem Cells 
Cellular injury following TBI is mostly related to an excessive inflammatory reaction near the 
injured area [241]. Galinda and colleagues reported a study of immunomodulatory properties of hMSC 
treatment [242] and results showed [243] downregulation of IL-6, and IL-10 mRNA levels in the acute 
setting but increased expression of IL-6 30 days after TBI. MSC transplantation into the injury site 
decreased the serum levels of IL-6, TNF-a, IL-4 and IL-10 in the acute phase of the model [244]. MSC 
secreted soluble factors capable of stimulating proliferation of NSC, in vitro, as well as increasing the 
expression of GFAP, a gene related to mature astrocytes, indicating that factors expressed by MSC 
could induce differentiation of NSC in vivo [245]. Zhang and colleagues designed a study to 
investigate the cerebral immunomodulatory effects of MSCs after TBI by systemic transplantation. 
They reported that injured cortex levels of proinflammatory cytokines IL-1β, IL-6, IL-17, TNF-α,  
IFN-γ and the chemokines MCP-1, MIP-2 after TBI were significantly decreased in the  
MSC-treatment group. Levels of the anti-inflammatory cytokines IL-10 and TGF-β1 were increased in 
the MSC-treatment group. There were no significant differences in levels of the cytokines IL-1α and 
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IL-4. The immunomodulation occurred because mRNA levels of NF-κB were decreased from 12 to  
48 h after MSC transplantation [246]. 
Bedii and colleagues performed an experiment to investigate the long-term effects of progenitor 
cells on microglia/macrophage phenotype and on the cognitive and motor functions of rodents after 
TBI. Each group was given two doses of its assigned multipotent adult progenitor cell therapy 
(MAPC) concentration at 2 and 24 h after controlled cortical impact (CCI) injury. They found 
improvements in average cognitive function as measured by Morris water maze (MWM) performance 
and motor function revealed by posture on the balance beam, and these were accompanied by localized 
reduction in numbers of activated microglia 120 days after injury. Both 24 to 120 h after TBI, MAPC 
treatment alters the ratio of proinflammatory microglia/macrophages to anti-inflammatory microglia/ 
macrophages in dentate gyrus [247]. 
6.1.5. White Matter Protection and Microvascular Integrity by Stem Cells 
Park Katya and colleagues designed a study of white matter protection and microvascular integrity 
of endothelial progenitor cells (EPC) after TBI [248]. They examined coronal sections of the corpus 
callosum for evidence of β-APP accumulation after FPI and treatment. A significant decrease was 
found in the endothelial progenitor cell treatment group. Accumulation of β-APP in brain regions is 
detected following TBI. Axonal pathology after TBI is characterized by impaired axonal transport 
resulting in β-APP accumulation, axonal swelling, and ultimately axonal disconnection. In addition to 
white matter outcomes, EPC treatment was studied for possible improvements of microvascular 
outcomes in the corpus callosum. There was a significant difference in mean total capillary lengths in 
the corpus callosum between groups. EPC treatment resulted in improved microvascular lengths of 
individually measured capillary fragments. Because mechanical shearing of tissues and subsequent 
ischemia are major factors after TBI, they practiced a sub-lethal stretch injury model to isolate the 
mechanical injury component on cortical neuron cultures to determine if EPC-conditioned media was 
sufficient to rescue axon degeneration. However, no protective effect on axonal degeneration was 
found. To model the ischemic component of TBI, They performed oxygen–glucose deprivation (OGD) 
in primary neuron cultures and reported that OGD neuronal cultures treated with EPC-conditioned 
media had a significant decrease in the number of degenerating axons relative to OGD alone. In order 
to confirm that the protective effects were a result of the endothelial progenitor cells and not a result of 
nonspecific proliferating cell effects, fibroblast-conditioned media was added to a subset of cortical 
neuron cultures. No rescue of axon degeneration was found to occur in cortical neurons subjected to 
OGD and treated with fibroblast-conditioned media. 
6.2. Nanotechnology Based Therapy 
Due to current advances in nanotechnology, neuroscience research has initiated application of 
nanotechnology as novel bioengineering therapies for the treatment of nervous system injuries 
including TBI. Our discussion includes newly-developed nanomaterials instead of reviewing the  
well-studied nanomaterial like sealants, fusogens, chitosan and hydrophilic, nonionic polymers 
(poloxamers, poloxamines, and polyethylene glycol). 
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6.2.1. Perfluorocarbons 
PerfluoroCarbons are formed of carbon and fluorine and emulsions and can easily be dissolved  
in large quantities of gases, including O2 and CO2 [249]. Previous studies displayed their ability  
to reduce infarct volumes and improve neurological function in experimental cerebral ischemic  
models when administered intravenously [250]. Zhengwen and colleagues conducted a study on 
neuroprotective effects of a 3rd generation perfluorocarbon, called oxycyte, following TBI in rats. 
They concluded that injured animals treated with a lower or higher dose of oxycyte had significant 
improvement in cognitive function, and injured animals that received either dose of oxycyte had 
significantly less neuronal cell loss in the hippocampal CA3 region. A lower dose of oxycyte 
significantly improved mitochondrial oxygen consumption levels. The same authors previously 
demonstrated that perfluorocarbons combined with 100% O2 treatment can significantly increase 
cerebral oxygenation and enhance mitochondrial function after lateral fluid percussion injury in a rat 
model [251]. The use of perfluorocarbons in TBI could prove beneficial for reducing neuronal loss as 
well as mitochondrial functioning and decrease the neurodegenerative effects caused by the injury. 
6.2.2. Polyethylene Glycol-Functionalized Hydrophilic Carbon Clusters (PEG-HCCs) 
PEG-HCCs are a class of biologically compatible carbon-based nanovectors which can be loaded 
with hydrophobic drugs, and when mixed with an antibody forms a noncovalent formulation capable 
of targeted drug delivery in vitro [252]. Marcano and colleagues conducted an in vitro study to 
evaluate the characteristics of PEG-HCCs designed specifically to address cerebrovascular dysfunction 
that accompanies TBI. The authors concluded that PEG-HCCs maintain antioxidant capacity sufficient 
for biological relevancy and targeting oxidatively stressed brain endothelial cells. When targeting the 
brain, they preserve their ability to alleviate oxidative stress in cultured brain endothelial cells [253]. 
Cell membrane repair mechanisms, advances to crossing the blood brain barrier, drug delivery to 
the injured brain, and nanostructure scaffolds for neural tissue engineering will be deterministic in the 
use of nanotechnology interventions as a prospective TBI treatment strategy. 
6.3. Preconditioning in TBI Treatment 
Prophylactic interventions involving methods of preconditioning (PC) may help individuals at high 
risk for brain injury or as a preoperative treatment for brain surgery, reducing the impact of primary 
and secondary brain damage [254]. For these reasons, translating basic science into chemical 
preconditioning allows clarification of the underlying mechanisms responsible for tissue tolerance and 
neuroprotection after cerebral injury, and may provide support for clinical applications. 
6.3.1. Hyperbaric Oxygen Treatment (HBOT) 
Hyperbaric oxygen therapy (HBOT) has been defined as a neurotherapeutic method for brain repair, 
providing oxygen-enriched air to patients in a closed chamber pressurized above one atmosphere 
absolute (1ATA). The combination of hyperoxia and hyperbaric pressure leads to significant 
improvements in tissue oxygenation as well as mitochondrial metabolism with anti-apoptotic and  
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anti-inflammatory effects [255–260]. HBO has proved to be neuroprotective against ischemic and 
hemorrhagic brain injury [261,262]. 
Wang and colleagues demonstrated that HBOT administered 2 days post injury resulted in 
significantly reduced overall neurological deficit scores and decreased neuronal apoptosis in brain 
tissues, and proposed the effective window for HBOT was 12 h post TBI [263]. Harch and colleagues 
tested 90-min sessions twice daily of HBOT at 1.5 ATA, starting 50 days after initial brain injury, and 
after 40 days of HBOT the MWM spatial learning performance in the HOBT groups improved 
significantly, and correlated with increased cerebrovascular density [263,264]. 
Harch and colleagues in 2010 reported dramatic improvement in a series of 15 patients treated with 
HBOT 1.5 in a clinical trial of military acquired TBI [265]. Multiple case reports show improvement 
in symptoms and functional brain scans for combat-related blast-related TBI [266,267]; hyperbaric  
oxygen-therapy (1.5 ATA) in treating sports related TBI/CTE was reported in two case reports [268].  
A randomized clinical trial of the use of HBOT in persistent post-concussion symptoms (PCS) in 
military service members was released in 2015. Their results support that supplemental administration 
of breathing 100% oxygen at 1.5 ATA or air at 1.2 ATA for 60 min is well tolerated and improves 
symptoms and quality of life compared with local care management of those without chamber 
intervention. However, there were no observed differences between HBOT and sham group receiving 
air at 1.2 ATA. These outcomes suggest that the observed improvements were not oxygen mediated 
but may reflect nonspecific improvements related to placebo effects. 
Discussions continue regarding the effectiveness of HBOT, but recent publications regarding the 
cognitive benefits of HBOT leave the medical community with an opportunity to pursue and conduct 
further research into its therapeutic benefits for the growing population of TBI. 
6.3.2. Glutaminergic Precoditioning 
Glutamate (N-methyl-D-aspartate) is known as the main excitatory amino acid in the central nervous 
system and its activation is one of the mechanisms of brain damage after TBI. Glutamatergic 
excitotoxicity contributes to primary and secondary damage [269]. PC using glutamate has been 
suggested as a mechanism of neuroprotection when given in low doses [270,271]. Glutamate PC 
provides protection not only against cellular damage by inducing a state of cellular tolerance to a 
future lethal event [272,273], but also induces the trophic effects of glutamate on neuronal cell 
reorganization [274]. Though one study reports finding impairments with long term memory, 
preventing excitotoxicity related to increased calcium influx stimulated by NMDA receptors is of 
paramount importance in halting the cascade of damage that follows TBI [275]. 
Based on the current research and findings, the mechanisms of NMDA-mediated preconditioning 
(NMDA-PC) include increased excitability, induction of mild oxidative stress, modulation of 
bioenergetics, ionic homeostasis and the modulation of glutamatergic transmission within  
non-excitotoxic levels. Although the neural mechanisms involved in NMDA preconditioning are not 
completely understood, literature has shown that there exists a time–dependent approach of  
NMDA-PC and that it is maintained up to 48 h after administration [276], showing upregulation of 
proteins related to bioenergetics (e.g., creatine kinase) and processing (Heat Shock Protein 70). 
l Doppler.e, proteins involved in synaptic vesicle neurotransmitter accumulation have been 
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downregulated. A study by Boeck and colleagues found that mitochondrial chain respiratory enzymes 
and creatine kinase may be associated with tolerance induction from previous NMDA preconditioning. 
TBI stimulation is decreased and ATP levels are maintained at a constant level by increasing the 
creatine kinase levels up to 24 after TBI [277]. 
Alterations in memory, cognitive, and mood impairments require a better understanding, and studies 
on the glutamatergic system are of paramount importance to clarify questions to reverse the pathologic 
cellular cascade underlying the progression of cell death. Prophylactic interventions involving PC may 
help individuals at high risk for brain injury or as a preoperative treatment for brain surgery [271].  
For these reasons, translating basic science into chemical preconditioning allows clarification of the 
underlying mechanisms responsible for tissue tolerance and neuroprotection after cerebral injury, and 
may provide support for clinical applications. 
6.4. Hormones in TBI Treatment 
6.4.1. Erythropoietin 
Erythropoietin (EPO) is a 34-kDa glycoprotein hematopoietic growth factor belonging to the type I 
cytokine superfamily [278], with receptors on neurons, glia cells, astrocytes, and cerebral endothelial  
cells [279–281]. It performs CNS functions such as limiting the production of MMP-9 activity, cell 
death, reactive oxygen species [282] and glutamate, reversal of vasospasm, neurotransmission modulation, 
promotion of angiogenesis [283–286], anti-inflammatory actions [280,287] and anti-apoptotic [288,289] 
properties due to antagonism to pro-inflammatory cytokines such as tumor necrosis factor [290,291]. 
Recombinant human erythropoietin (rhEPO) plays protective roles in TBI including enhancing 
neurogenesis, restoring spatial memory [287], reducing neuronal apoptosis, down-regulating activation 
of glial cells and complement receptor type 3 [292], attenuating necrosis volume [293], modifying the 
endogenous indices of oxidative stress [294] and protecting the ultrastructure of pneumocyte type II 
cells [295]. It also improves functional outcomes via an increase in the mobilization of endothelial 
progenitor cells and in subsequent angiogenesis [296]. 
The effects of EPO on animal models proved to have positive effects on neuroprotection following 
TBI. EPO and analogs can reduce lesion volume and improve neurobehavioral outcomes in animal 
models of TBI. Due to recent clinical trials supporting the use of EPO associated with reduced 
mortality in trauma patients [297] and findings that link EPO-amplified neurogenesis with improved 
spatial learning following TBI, as well as attenuating necrosis volume, it has become an attractive 
treatment for TBI, reaching the main goal of neuroprotection: to prevent or decrease secondary damage 
and stimulate repair through enhancing adult endogenous neurogenesis. 
Clinical trials on the efficacy of EPO treatment in patients with TBI yield conflicting results, and 
without rigorous, fine-tuned, and detailed preclinical evaluation, it is unlikely that novel neuroprotective 
drugs will prove effective when tested in large, time-consuming, and expensive human clinical trials. 
Because of its promising results in preclinical studies, it is important to improve the methodological 
quality of pre-clinical studies in order to efficiently progress towards EPO treatment in humans. 
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6.4.2. Progesterone 
Progesterone (PG) is a well-known hormone that functions primarily on the reproductive system. 
Recent decades have given new hope to its use besides its function as sex hormone. It has been found 
to act in several models of TBI, serving as a neuroprotector [298]. Thus, it gives justice to the name 
Baulieu coined, back in 1996, referring to it as a neurosteroid, as it is both synthesized de novo or from 
precursors in the brain [299]. This neuroprotective hormone is produced in the brain by neurons and 
glial cells, and the latter is the cell by which its neuroprotective actions are believed to derive. Cerebral 
edema, inflammation, apoptosis and oxidative stress include some of the pathophysiologic changes 
that occur after TBI. Not only acting as an anti-oxidant and upregulating GABA (neurotransmitter),  
PG seems to provide additional neuroprotection by reducing cerebral edema, and decreasing 
inflammation and apoptosis. Reducing inflammation is achieved through downregulating the 
expression of proinflammatory cytokines though microglia and astroglia. Cerebral edema is reduced, 
in part, by regulating the expression of aquaporin 4 (a water channel) present in astrocytes [298]. 
PG has been tried in clinical trials due to its pluripotential role after multiple animal studies 
supported its use in TBI. Phase II clinical trials have shown improvements in patients with TBI after 
treatment with PG including decreased mortality rate and increased functional independence scores 
when compared to placebo or healthy controls, respectively in moderate and severe TBI [300,301]. 
ProTECT started as a phase II clinical trial and established safety of the drug; thirty-day mortality in 
the treatment group was less than half that of the control group and moderately injured patients in the 
treatment group achieved better Glasgow Outcome Scale-Extended and Disability Rate Scale score 
than the placebo group [300]. 
In 2007, Wright and colleagues started ProTECT III, but found that after stratification of the 
patients based on severity of injury, no improvements in recovery were noted after giving progesterone 
or placebo to patients within four hours of injury, continuing treatment for 96 h, and the study was  
stopped [302]. Another recent Phase III clinical trial called SYNAPSE also concluded that PG had  
no benefit in severe TBI [303]. These randomized phase III clinical trials on severe TBI by Skolnick 
and colleagues in 2014 and Wright and colleagues in 2007, based on the premise that PG used in 
experimental animal studies shows reductions in cerebral edema along with anti-inflammatory and 
antiapoptotic effects that limit secondary injury. Through early administration of progesterone, these 
secondary injuries involved in TBI might be avoided. The SYNAPSE clinical trials showed no 
significant difference on the Glasgow Coma Scale (GCS) between the placebo and progesterone 
treatment given within 8 h of injury [302]. The outcomes of these trials require the medical community 
to rethink the standardized measures used to quantify TBI (GCS and Marshall classification) and move 
towards a more multidimensional approach for an individualized treatment [303]. 
In conjunction with this and other reports, the dynamics of TBI stretch beyond a monotherapeutic 
approach to target single receptors or specific mechanisms [304,305], and an approach that 
encompasses both the multiple direct and indirect injury mechanisms must be developed in order to 
provide effective treatment for TBI [303]. 
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6.5. Antioxidants in TBI Treatment 
Recently, the literature reveals more options in TBI treatment with the use of antioxidants in the 
clinical setting in the near future. 
6.5.1. U-83836E 
The first antioxidant to mention is U-83836E a non-steroidal compound that functions as a 
lipopolysaccharide (LP) inhibitor and free radical destroyer. It not only decreases posttraumatic LP and 
preserves mitochondrial respiratory function, but also has calcium buffering capacities [306]. Its 
capacity to inhibit calpain-mediated cytoskeletal degradation in CCI TBI in mice has been recently 
acknowledged in the literature. This explains the detailed interaction between disruptions in neuronal 
Ca2+-homeostasis and posttraumatic LP and calpain mediated cytoskeletal damage [307]. These are 
inhibited by U-83836E, thereby preventing a cascade of secondary injury and allowing neuroprotection 
to take on a positive role in TBI. 
6.5.2. Melatonin 
Melatonin has been well studied in the field of circadian rhythms and sleep; its functions in the 
brain also give it neuroprotectant qualities. It acts as both a direct scavenger of free radicals and an 
indirect regulator of endogenous enzyme expression [308]. Advantages of melatonin as a CNS injury 
therapeutic include its lipophilicity, brain penetrability, and low potential for side effects [309]. In TBI 
models, melatonin increased antioxidant levels in the brain, decreased NF-Kappaβ activation and 
improved cognitive function [310–312], though a combination of melatonin and minocycline in rat 
CCI model did not show benefits in cognitive function using melatonin alone or in combination. 
6.5.3. Tempol 
Tempol, a stable membrane permeable nitroxide, has a 1 h to several days treatment window to 
achieve mitochondrial protection [313] and locomotor recovery respectively [314], and is also 
associated with the metabolism of many reactive oxygen species and reactive nitrogen species 
(ROS/RNS) in CCI-TBI model [315,316]. Tempol is able to reduce posttrauma LP and protein  
nitration-induced oxidative damage, allowing preservation of mitochondrial bioenergetics, and decrease 
calpain mediated cytoskeletal damage, thereby decreasing neurodegeneration [317]. Furthermore, 
Tempol decreased brain edema and improved neurological recovery in rat contusion head model. 
6.5.4. Resveratrol 
Resveratrol, known to be present in high amounts in red wine and grapes, has since early 2000 
emerged as a potential antioxidant with neuroprotective effects. Resveratrol shows promising abilities 
as a neuroprotective agent in TBI models, possibly inhibiting lipid peroxidation [318–320]. The use of 
resveratrol in an experimental model of TBI was able to counteract oxidative damage and prevent the 
depletion of the antioxidant glutathione and also resulted in a reduction of infarct area [321]. The use 
of antioxidants in sequestering ROS and other harmful molecules is a promising strategy to increase 
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neuroprotection in TBI [318]. Part of the antioxidant effect of exogenous substances such as flavonoids 
may be due to the induction of endogenous antioxidants. Nrf2 activators may be prime candidates for 
the attenuation of oxidative stress and subsequent neurotoxicity induced by TBI [322]. 
6.6. Hypothermia 
Since 1943, inducing hypothermia as a treatment in which body temperature is kept at 32–34 °C  
has been applied in various brain injuries aiming to decrease brain metabolism and reduce neuronal 
swelling [323]. Interventions achieving a more modest temperature reduction than induced hypothermia 
include drug therapies (e.g.,: paracetamol, acetaminophen, non-steroidal anti-inflammatory drugs [324]) 
and physical therapies (e.g.,: bedside fans, tepid sponging, ice packs, cooling blankets [325]). Studies 
in recent years used different temperature ranges in order to achieve good patient outcomes. Improving 
patient outcomes is also linked to prevention of cerebral hypoxia after TBI [326]. Induced hypothermia 
aims to fight against such detrimental effects [327,328], and positive results were achieved by reducing 
hypoxic events following TBI with the use of brain tissue oxygen–guided cerebral perfusion pressure 
management and therapeutic mild hypothermia (predefined as 33–35 °C) [329–332]. Hypothermic 
patients had lower values than normothermic individuals. A slow rewarming over 24 h after rapidly 
achieving the target therapy prevented acute worsening of intracranial hypertension in the first 72-h 
following TBI [333,334]. A study done by Takashi and colleagues [335] concluded that temperature 
control of 35–35.5 °C is sufficient to control intracranial hypertension without inducing cardiac 
dysfunction and oxygen debt [336]. Thus, hypothermia may reduce intracerebral pressure earlier than  
a 72-h window and decrease TBI induced inflammation. 
Even though the mechanisms responsible for the actions of hypothermia in the treatment of TBI 
remain to be elucidated, mild induced hypothermia seems to have an association with the expression 
connexin-43 and glutamate-transporter-1 in the hippocampus following TBI in rats. Mild hypothermia 
improved TBI induced brain edema and neurological functional deficits, and it is accompanied by  
down regulation in expression of connexin-43, normally increased after TBI, and upregulation  
of glutamate-transporter-1 levels that are normally decreased following TBI [337]. In accordance  
with previous studies, a model of fluid percussion injury, post-traumatic hypothermia significantly 
attenuated cell death within the hippocampus and attenuated caspase-3 upregulation, thereby reducing 
markers of apoptosis [338]. 
A review by Cochrane and colleagues concluded that there is no evidence that induced hypothermia 
is beneficial in the treatment of traumatic head injury [339]. In addition, it suggested that there is an 
increase in pulmonary infections with the intervention of hypothermia compared to controls [340].  
While considering the numerous variables in different clinical trials, the Brain Trauma Foundation 
states that six clinical tries of moderate quality did not clearly associate hypothermia with consistent 
and statistically significant reductions in mortality, but did find benefit in the fact that the same 
patients were more likely to have favorable neurological outcomes, defined as GCS scores of 4 or 5.  
In addition, it suggested that hypothermia may reduce mortality if cooling is maintained for more than  
48 h [341]. 
There are two large ongoing trials of long-term hypothermia for TBI. One is the Eurotherm 3235 
trial in Europe [323]. Hypothermia of 32–35 °C will be continued for at least 48 h until ICP is 
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stabilized at normal level and then the patients will be re-warmed at a rate of 1 °C/4 h. The other is the 
POLAR trial for severe TBI patients. In this study, within 3 h of injury the patient will be rapidly 
cooled down and then maintained at 33 °C for 3 days [342]. Rewarming will occur at a rate of  
0.17 °C/h and will be titrated to intracranial pressure (ICP) control. Results of this clinical trials aim to 
clarify questions remaining in regards to the role of hypothermia in TBI. Challenges still remain, and  
a multicenter randomized trial needs to be undertaken in order to clear the debate in regards to the 
mechanisms of hypothermia in relation to TBI. Further investigations into hypothermia could provide 
information on the benefits and protocols for optimal use not only in each age bracket, but also 
according to intensity of injury. 
6.7. Inhibitor Interventions for TBI Treatment 
6.7.1. CR8 
CR8 is a CDK (cyclin-dependent kinase) inhibitor and second-generation analog with promising 
therapeutic potential [343]. It has been used in research using the lateral fluid percussion injury (LFP) 
model of TBI and enables DNA synthesis in neurons, microglia/macrophages and astrocytes to  
occur [344] after 7 and 14 days post TBI. The involvement of cell cycle activators (CCA) in the 
pathological mechanisms of neuronal cell death with the CNS has been reported [345–350]. After  
LFP injury, CR8 downregulates the expression of cell cycle markers such as CDK1, n-myc  
phosphorylation [349], and other cell cycle proteins [350–352]. Neuroprotection is achieved by reducing 
CCA upregulation in neurons through the inhibition of CDKs through CR8. On neurobehavior tests, 
CR8 improved memory retention and reduced LFP-induced impairment in fear-based contextual  
and emotional memory function in the passive avoidance task [353]. CDK inhibition significantly 
improves hippocampal neuronal survival [348–350]. Furthermore, CR8 preserves neurons in the 
hippocampus and surrounding areas, resulting in cognitive improvements. Signs of depression 
normally present in LFP injured rats were greatly reduced with treatment of CR8. At the cellular level, 
CR8 decreases microglia and astrocyte activation, thereby preventing further damage to the CNS. 
Cell cycle activators and their role in increased neurodegeneration and chronic neuroinflammation 
now face a strong opponent. CR8 is able to fight the pathophysiology of TBI, and combat the S-phase 
induction of cells that happens with CCA induced TBI as seen in the LFP model [353]. In conclusion, 
selective CDK inhibitors bring promise to treatment options for TBI in the clinical setting through its 
multi-faceted neuroprotective capacities associated with inhibition of CCA-dependent neurodegeneration 
and neural cell associated inflammation. 
6.7.2. Statins 
Statins are 3-hydroxy-3-methylglutaryl coenzyme A (HMGA) reductase inhibitors, and not only  
act to reduce cholesterol, but influence both the acute and chronic phases of TBI [354–360]. A series 
of effects can be achieved through the use of statins on brain edema, BBB integrity and brain 
microvascular endothelial cells [361], cerebral blood flow, neuroinflammation, axonal injury, cell 
death, and trophic factor production. This is made possible by the influence statins have on several 
molecular outcomes such as TUNEL staining, CREB, Akt, eNOS, FOXO1, NF-kB, GSK3, cytokines, 
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BrdU labeling, blood vessel formation, and vascular endothelial growth factor and increased 
expression and secretion of tissue inhibitor of metalloproteinase-1 and 2 [357,360]. 
Studies show improvements in behavior and histology with atorvastatin and simvastatin. 
Atorvastatin has a longer half-life and active metabolites for greater protection against neuronal  
death than simvastatin [362]. Despite this, Lu and colleagues reported simvastatin promoted less 
hippocampal CA3 cell death and improved MWM performance after CCI when compared to 
atorvastatin [363]. In concordance with Lu and colleagues other studies have shown simvastatin to 
better penetrate BBB. Wang and colleagues found in 2007 that atorvastatin and simvastatin decreased 
functional neurological deficits after TBI in mice, with improvements in short-term and long-term 
functional performance through the preservation of hippocampal neurons seen on histology, and 
inhibition of inflammatory cytokine MRNA expression in brain parenchyma. In addition, statins not 
only improved cerebral hemodynamics after TBI, but also contributed to improvements involving the 
decreased cerebral perfusion state that happens following TBI in pretreatment conditions [362]. 
According to studies done by Ramirez and colleagues 2011 simvastatin is the most effective statin.  
It has the power to decrease inflammation [364], increase cerebral diameter of vessels around the 
lesion site, and increase proliferation of endothelial cells in the neurogenic regions while decreasing 
neuronal loss in non neurogenic regions of hippocampal CA3 regions after TBI [365]. Simvastatin and 
atorvastatin improve behavioral outcomes, reduce hippocampal degeneration, and improve cerebral 
blood flow after experimental traumatic brain injury [362]. 
Plausible explanations for neurologic recovery lies in the understanding that simvastatin may  
enhance proliferation and neurogenesis as shown in cultured neural cells, and is able to increase the 
expression of notch-1 proteins, demonstrated in chronic simvastatin treatment [366]. In addition, 
neural cell division in the dentate gyrus and subventricular zone guarantees regeneration of neurons in 
the CNS [367]. Simvastatin induced both astrocytic and neuronal differentiation during in vitro 
experiments, but quantitative data shows that simvastatin significantly increased neuron populations. 
In addition, previous studies have shown that simvastatin inhibits the activation of microglial cells and 
astrocytes after TBI [360]. 
Currently, atorvastatin is undergoing a phase II clinical trial with a 7-day regimen in order to help 
fill in the gaps regarding efficacy of treatment in the months following TBI. Though the effects of 
chronic administration of statins are still unknown in the literature, its ability to decrease neuronal cell 
loss and control inflammation are favorable and offer a novel therapeutic strategy for acute TBI after 
closed head injury. 
6.7.3. Acetylcholinesterase Inhibitors 
Neuroinflammation is one of the major causes for increased neuropathology and neurobehavioral 
changes after single or repeated exposures to blast activity [368–373]. Recent studies on alterations of 
acetylcholinesterase activity in specific areas of the brain in mice after repeated blasts prompted 
researchers to evaluate gene expression related to cholinergic and inflammatory pathways [374]. 
Significant down-regulation of cholinergic receptors including muscarinic 2 and nicotinic alpha 7 
occurred in the midbrain of mice exposed to repeated blasts. Muscarinic and nicotinic alpha 7 
acetylcholine receptors are essential elements of the anti-inflammatory pathways and down-regulation 
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of these receptors in the midbrain region after blast induces the pro-inflammatory pathways leading to 
neuropathology and neurobehavioral deficits [375–377]. Concurrently, GABA and glutamate receptors 
in the midbrain are down-regulated after repeated blast exposure. Pro-inflammatory cytokines  
and chemokines are released both centrally and peripherally after blast exposure [369,370,378]. 
Furthermore, significant up-regulation of multiple interleukins, tumor necrosis factor, and their 
receptors during cDNA microarray analysis of various brain regions of repeated blast exposed mice 
showed confirmed the presence and initiation of pro inflammatory pathways. The pro-inflammatory 
marker for myeloperoxidase expression was significantly higher in the cerebellum of blast exposed 
mice [347]. Currently, there are no clinical trials exploring the uses of ACE inhibitors after TBI. 
6.8. Lithium Used for TBI Treatment 
Neuroprotective in nature, and acting across multiple pathways, lithium serves as a potential 
therapeutic agent for treatment of neurological deficits and damage, as well as neuronal protection  
and functional recovery after TBI [379]. Patients with TBI often suffer from depression, a disease  
found to reduce brain levels of BDNF [380,381], but lithium is able to increase BDNF levels in the  
brain [381–384]. Lithium increases nerve growth factor (NGF) in the rat frontal cortex, hippocampus, 
amygdala, and forebrain [382,383,385–387], as well as vascular endothelial growth factor (VEGF), 
throttling an increase in the number of astrocytes, oligodendroglia, neurons, and decreasing the size of 
the lesion thereby improving functional outcomes [388–390]. Lithium prevents stress-induced 
reductions in VEGF levels, thereby stimulating neurogenesis and angiogenesis. In preclinical  
studies, both chronic [391,392] and short-term uses of lithium have been found to activate  
neurogenesis [393]. In addition, therapeutic levels of lithium stimulate proliferation of nestin-positive 
progenitor cells in brain neurons [394], as proliferation of adult hippocampal progenitor cells involving 
Wnt/beta-catenin activation occurred after GSK-3-beta-inhibition [395]. TNF-alpha directly disturbs 
BBB integrity, leading to secondary injuries including cerebral edema and leukocyte infiltration [396]. 
A study performed investigating the effects of etanercept and lithium chloride found decreased  
TNF-alpha activity with subsequent decrease in cerebral damage after administration of the therapeutic 
agents [396]. 
TBI often leads to not only acute injury but also long-term neurodegeneration, and is one of the major 
risk factors for developing Alzheimer’s disease (AD). A strong indication of AD or neurodegeneration 
includes the presence of Beta amyloid (AB) peptide deposits, and these deposits increase after TBI in 
animal models and in patients with head trauma [396]. Because of lithium’s ability to inhibit GSK-3 
activity, it can reduce beta amyloid peptide deposits [397]. In a study on an animal model of TBI, mice 
were treated with lithium after TBI and there was a reduction in beta amyloid load through B-secretase 
inhibition. BACE1 is the major B-secretase involved in production of beta amyloid in neurons [398], 
and BACE1 levels increase after TBI in both human and rat models [399–401]. The use of lithium 
after TBI blocked BACE1 expression, thereby reduced the AB load. This, in part, contributed to 
improved spatial learning and memory with increased hippocampal preservation as determined by 
improved neurobehavioral testing compared to TBI and sham groups [397]. 
Regulation of histone deacetylase (HDAC) inhibition regulation is neuroprotective in nature 
through its ability to restore histone acetylation levels and correct transcriptional deficits in various 
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models of brain disorders, specifically TBI rodent models [402–405]. A recent study in 2013 by 
Fengshan and colleagues indicated that the effects of combined subtherapeutic valproate  
(VPA)–another mood stabilizing drug–and lithium in a mouse model of TBI [406]. Both lithium  
and VPA maintain the BBB through inhibition of both HDAC and TBI-induced MMP-9  
overexpression [407,408]. The combined treatment of sub-effective doses of both lithium and VPA 
significantly reduced lesion volume while preserving BBB integrity three days post TBI. This was not 
observed in the groups with lithium or VPA alone. However, lithium alone showed improvements in 
fine motor neurobehavior at days 14 and 21, while combined treatment had more profound effects with 
significantly fewer Fluoro-Jade B (FJB)–a dye used to label degenerating neurons-positive cells at 
days 7, 14, and 21 [406]. The advantage of subtherapeutic levels of both drugs causes less side effects, 
improves tolerance to long term use, and targets the different cell pathways involved in the complex 
pathophysiology of TBI [409]. 
7. Conclusions 
TBI research literature is published every year in great quantity and animal models of TBI are 
essential to clarify underlying injury mechanisms, to assess the safety and efficacy of novel  
therapies prior to clinical trials [410] and to better understand the injury mechanism that drive its 
progression [411]. This indicates the urgency to explore optimal combinations of preventive and 
therapeutic measurements for TBI. In this review, we stress updates in TBI tracing, monitoring and 
treatment while updating the historical progress in these areas. The past decades witnessed tremendous 
advances in all those areas described in this review. 
TBI is a complex and heterogeneous disease that requires personalized tracing, monitoring and 
treatment in clinical practice according to the severity, course, age, gender and co-morbidities 
associated with injury. An individual specific therapeutic option would benefit TBI victims to achieve 
the ideal structural restoration preserving lives and decreasing not only costs but also long term 
comorbidities associated with this condition. 
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